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ABSTRACT 
 
Ryan Thomas Dackor: Genetic Mouse Models Reveal Key Physiological Functions 
of Adrenomedullin Signaling 
 
 
(Under the direction of Dr. Kathleen M. Caron) 
 
 
Adrenomedullin (AM) is a potent 52-amino acid peptide vasodilator that is 
involved in a wide variety of physiological processes, including regulation of renal 
function, neurotransmission, apoptosis and growth.  AM peptide levels are elevated 
in many cardiovascular conditions, including normal pregnancy, septic shock, 
hypertension, and renal failure.  The multitude of conditions associated with elevated 
AM levels suggests that it serves to maintain physiological homeostasis during 
various stresses.  AM exerts most of its biological functions by promoting increases 
in the intracellular messengers, cAMP and/or nitric oxide.  Recent characterization of 
AM signaling has identified a unique mechanism of G-protein coupled receptor 
signaling, mediated by a class of single transmembrane proteins called receptor 
activity modifying proteins (RAMPs), that have been shown to dictate ligand binding 
specificity of the calcitonin receptor like receptor (CLR for protein, Calcrl for gene).  
To date, three RAMP proteins have been identified and it is the association of 
RAMP2 or 3 with CLR that designates an AM receptor.  
My research has utilized several lines of gene targeted mice to determine the 
in vivo role of AM and its signaling components in various physiologic contexts.  I
 ii
show here that mice lacking CLR suffer from extreme hydrops fetalis and die at mid-
gestation with severe cardiovascular defects, including small overall heart sizes, thin 
vascular smooth muscle cell walls and defects in myocardial proliferation and 
apoptosis.  To further examine the role of CLR in cardiac development and 
physiology, I crossed mice with a floxed Calcrl allele to two cardiomyocyte-specific 
Cre lines, α-MHC and cardiac troponin.  These mice develop normally and are born 
at the expected Mendelian ratios.  Additionally, echocardiography and histological 
examination revealed no significant differences in heart structure or function as late 
as 14 weeks of age.  Cardiomyocyte-specific CLR knockouts and control littermates 
also responded similarly to cardiac challenge in two different disease models: 
transverse aortic constriction and angiotensin II infusion.  A separate study revealed 
that RAMP2 and RAMP3 have distinct physiological functions from embryogenesis 
to old age, whereby genetic deletion of Ramp2 results in embryonic lethality while 
deletion of Ramp3 has no effect on embryonic development or survival.  Finally, I 
used mice heterozygous for the AM gene to show that the AM peptide is required for 
the normal inflammatory response to LPS-induced septic shock.  Collectively, the 
work presented here provides the first in vivo genetic characterization of several key 
genes involved in AM signaling during various physiological conditions.    
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CHAPTER 1 
 
INTRODUCTION
Adrenomedullin: A Multifunctional Peptide  
 
Adrenomedullin (AM) is a highly conserved, 52-amino acid peptide 
vasodilator that was first isolated from human pheochromocytoma in 1993 (45).  
Kitamura et al. discovered the peptide based on its ability to stimulate cAMP 
production in human platelets and maintain potent hypotensive activity in the rat.  In 
addition to its vasodilatory activity, AM is involved in a wide range of other 
physiological actions including bronchodilation (38), renal function (72), 
neurotransmission (77), growth and apoptosis (80).  AM is produced and secreted 
by almost all mammalian tissues and cell types, but it is most highly expressed in 
cardiovascular tissues such as the heart (35), lungs (76) and vasculature (88, 90).  
Stimuli for AM synthesis and secretion include inflammatory cytokines such as TNF-
α and IL-1β (89), angiotensin II (75), endothelin-1 (75), hypoxia (25) and oxidative 
stress (2).  Results from our literature summary of over 60 publications highlights the 
important role AM plays in various diseases and physiological conditions, especially 
cardiovascular disease, hepatic and renal disease, normal pregnancy and sepsis, 
where AM plasma levels are elevated at least 2-fold (Figure 1.1).  The multitude of 
conditions associated with elevated AM levels suggests that it may serve as a 
protective response to primary cardiovascular stress.  In Japan, the AM peptide is 
already being used as a beneficial hemodynamic regulator for patients suffering from 
congestive heart failure (58).  Therefore, AM is quickly becoming recognized as a 
ubiquitously expressed, dynamic peptide that can impact on several normal and 
pathological conditions. 
AM Receptors and Signal Transduction 
 2
Biochemical and pharmacological studies on AM signaling has led to the 
characterization of a unique mechanism of G-protein coupled receptor signaling.  
However, the identification of a bona fide AM receptor has been difficult.  Three 
putative AM receptors have been identified and suggested to mediate AM signaling 
based on their ability to bind the peptide and trigger an increase in cyclic AMP 
(cAMP) levels following AM treatment.  One of these receptors, known as L1, binds 
to AM with a KD of 8.2 X 10-9 M and mediates a cAMP response when expressed in 
COS-7 cells treated with the peptide (40).  It is co-expressed with AM in most 
tissues, but in neonatal cardiomyocytes it is expressed at significantly lower levels 
than the other two putative AM receptors (4).  Another receptor, RDC-1 was 
originally identified as a calcitonin gene-related peptide (CGRP) receptor, but also 
binds to AM at a KD of 1.9 X 10-7 M and mediates a cAMP response to AM in COS-7 
cells (41).  A third receptor, known as the calcitonin receptor-like receptor (CLR, 
protein; Calcrl, gene), was cloned by several groups (1, 21), but inconsistent binding, 
expression, and functional results with AM and/or CGRP peptides confounded its 
declaration as a unique AM receptor (1, 17, 18, 21, 67).  Several studies also 
contested the roles of L1 and RDC-1 as AM receptors (37, 43, 50, 52). 
These discrepancies were eventually resolved with the identification of a 
class of single transmembrane proteins called receptor activity modifying proteins 
(RAMPs) that have been shown to dictate ligand binding specificity of CLR (52).  To 
date, three RAMP proteins have been identified.  As shown in Figure 1.2, when 
RAMP1 associates with CLR, a calcitonin gene-related peptide (CGRP) receptor is 
produced.  On the other hand, association of RAMP2 or RAMP3 with CLR results in 
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a receptor that is specific for the AM peptide.  CLR and the RAMPs are expressed in 
a variety of cell types and it is the spatial and temporal expression patterns of the 
RAMP proteins that determine how a cell will respond to either CGRP or AM.   
The biochemistry and pharmacology of the RAMP-receptor interaction have 
recently been extensively reviewed by Hay et al. (22).  Although the three 
mammalian RAMPs vary greatly in sequence homology (<30%) and tissue 
distribution (52, 79), they share a similar molecular mass (160 amino acids) and 
structure, which consists of a long extracellular amino terminus, a single 
transmembrane domain, and a short cytoplasmic carboxy terminus.  The RAMPs 
have a broader tissue distribution than AM and CLR, which likely reflects the fact that 
RAMPs can interact with other class II GPCRs such as calcitonin (11), vasoactive 
intestinal peptide/pituitary adenylate cyclase activating peptide 1, glucagon, PTH 1 
and 2 receptors (10), and a class III GPCR called calcium-sensing receptor (5).  
Large scale, tissue-specific analysis of the human and mouse transcriptomes reveals 
that RAMP2 is among the top 10 genes the expression pattern of which correlates 
with that of CLR, suggesting that most CLR is complexed with RAMP2 to form a 
functional AM receptor (19, 87). 
The first in vivo genetic evidence that CLR serves as the primary AM receptor 
is reported in this thesis (15).  Briefly, gene targeting methods were used to generate 
and characterize mice lacking expression of the Calcrl gene.  These mice die at mid-
gestation from hydrops fetalis (generalized edema) and cardiovascular defects 
including thin vascular smooth muscle cell walls, small overall heart sizes and 
defects in cardiac proliferation and apoptosis.  Interestingly, these defects almost 
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identically “phenocopy” those of the previously reported AM knockout mice (6) and 
provide compelling evidence that CLR acts as a bona fide AM receptor during 
embryonic development.  
In a similar fashion, the validation of RAMP2 as a required component for AM 
signaling was also demonstrated by our laboratory (14).  Briefly, Ramp2 knockout 
mice die at mid-gestation with generalized edema that is remarkably similar to that 
seen in AM and Calcrl knockouts.  Taken together, these in vivo studies define the 
receptor components required for AM signaling.  In a surprising contrast, genetic 
deletion of Ramp3 did not phenocopy the AM, Calcrl and Ramp2 knockout mice.  As 
presented in this thesis, apart from lean body mass at old age, Ramp3 knockout 
mice appear mostly indistinguishable from their littermates.  Therefore, the 
importance of RAMP3 in AM-mediated signal transduction remains to be 
determined.     
 
Regulation of Growth and Apoptosis by AM 
AM has various effects on cell growth and apoptosis (80), depending on cell 
type and experimental conditions.  Conflicting results have been reported on the role 
of AM in vascular smooth muscle cell (VSMC) proliferation.  Kano et al. showed that 
AM inhibits serum-stimulated proliferation of rat VSMCs through a cAMP-dependent 
process. (39)  Another study by Upton et al. reported significant growth inhibitory 
effects of AM in platelet-derived growth factor (PDGF)-stimulated pulmonary artery 
smooth muscle cells (99).  On the other hand, serum-deprived VSMCs responded to 
AM by synthesizing DNA and increasing the rate of proliferation.  These responses 
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were independent of cAMP activation but were mediated by activation of the 
p42/p44 mitogen-activated protein kinase pathway (31).  AM knockout mice have 
thinner VSMC walls than their wild-type littermates, providing in vivo evidence that 
AM is required for normal VSMC growth (6).  Additional work, presented in this 
thesis, shows that Calcrl knockout mice also have thin VSMC walls caused by 
reduced proliferation, further supporting the role of AM signaling in VSMC growth 
(15).  
The endothelium is a primary source of AM (88) and several studies have 
shown that AM plays a protective, pro-survival, anti-apoptotic role in endothelial 
cells.  A study by Shichiri et al. demonstrated an anti-apoptotic role for AM in serum-
deprived rat endothelial cells, whereby AM treatment induced expression of the pro-
survival protein, Max (81).  Furthermore, inhibition of cAMP or the addition of other 
cAMP elevating agents such as prostaglandin I2 or forskolin had no effect on 
apoptosis, suggesting that the anti-apoptotic activity of AM in this model was 
independent of cAMP.  Another group also observed a cAMP-independent role for 
AM in preventing apoptosis in cultured human umbilical vein endothelial cells.  In 
their experiment, Sata et al. found that the anti-apoptotic effect of AM was abrogated 
by L-NAME, but not by guanylate cyclase inhibition, suggesting an NO-dependent, 
cGMP-independent mechanism (78).  In addition to regulating apoptosis, AM has 
also been shown to stimulate proliferation of endothelial cells (55, 56); a process that 
is important in angiogenesis and vascular remodeling of injured blood vessels.   
The effects of AM on cardiomyocyte growth and apoptosis have also been 
well documented.  AM prevents cardiac hypertrophy by inhibiting protein synthesis in 
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cardiomyocytes (97).  Tokudome et al. demonstrated that AM inhibits doxorubicin-
induced apoptosis in cardiomyocytes via a cAMP dependent mechanism (94).  Two 
other reports also showed that AM attenuates myocardial apoptosis following 
ischemia-reperfusion in the rat via activation of the Akt-GSK pathway and reduced 
caspase-3 activation (68, 111).  Work presented here shows that AM and Calcrl 
knockout mice have smaller overall heart sizes with reduced proliferation and 
increased apoptosis, supporting a pro-survival effect of AM signaling in the heart.  
 
AM in Cardiac Function 
Several studies have focused on the role of AM in cardiac function.  Because 
systemic infusion of AM reduces peripheral resistance (61) (29), it has been difficult 
to determine whether AM has a direct effect on cardiac function or if the effects are 
secondary to reduced afterload.  One group examined the effects of AM on blood 
pressure and changes in diastolic and systolic function following long-term 
administration of angiotensin II (Ang II) or norepinephrine in rats.  They showed that 
AM suppressed the increase in blood pressure and augmented the improvement of 
systolic function induced by Ang II, but did not affect the development of left 
ventricular hypertrophy or cardiac gene expression (51).  Another study showed that 
intravenous administration of AM enhanced left ventricular myocardial contraction 
and improved left ventricular relaxation without increasing myocardial oxygen 
consumption in patients with left ventricular dysfunction due to myocardial infarction 
(57).   
 7
Whether or not AM directly effects myocardial contractility, which would also 
contribute to enhanced cardiac function, is still controversial.  Ikenouchi et al. 
showed that AM reduces contractility in rabbit ventricular myocytes by stimulating 
NO production, thereby decreasing intracellular Ca2+ concentration through a cGMP-
dependent mechanism (28).  On the other hand, AM has been shown to have a 
positive inotropic effect on isolated perfused rat heart and isolated rat papillary 
muscle (27, 91).  Szokodi et al. reported that AM enhances myocardial contractility 
by stimulating Ca2+ release from intracellular ryanodine- and thapsigargin-sensitive 
Ca2+ stores, activating protein kinase C and increasing Ca2+ influx through L-type 
Ca2+ channels (91).  Other studies have shown no inotropic effect (85) or even a 
dual inotropic effect, due to a switch from Gs to Gi coupling of the receptor after 
prolonged (30 minutes) exposure to AM (54).  These contradictory results may be 
due to different experimental conditions and assay readouts.  Some studies base 
their results on developed tension in muscle, while others measure individual cell 
shortening and/or intracellular Ca2+ levels in isolated cells.  In addition, model 
species, amount of AM peptide used for treatment and method of muscle stimulation 
have varied across studies.  No genetic models have been used to test the direct 
role of AM signaling in cardiac function.  This thesis addresses the issue by using 
control and cardiomyocyte-specific Calcrl knockout mice to determine the role of AM 
signaling in overall heart function and cardiomyocyte contractility.   
 
AM in Heart Disease 
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 As previously stated, AM peptide levels are significantly elevated in a 
multitude of diseases, including cardiovascular disease.  In patients with congestive 
heart failure, the concentration of plasma AM directly correlates with disease 
severity (36, 42, 63).  In fact, AM has been identified as an independent predictor of 
prognosis in these patients (73).  Furthermore, AM levels can be used to determine 
which patients should receive β-adrenergic antagonists for treatment of ischemic left 
ventricular dysfunction, since subjects with high AM benefit more from such 
treatment (74).  Although AM is produced by various tissues, several studies 
suggest that myocardial AM production is a primary source of high plasma AM in 
patients with heart failure.  AM immunoreactivity was higher in myocardial tissue 
obtained from heart transplant recipients with severe heart failure than from healthy 
donors (36).  Unlike healthy subjects, patients with heart failure have markedly 
higher AM concentrations in coronary sinus (which receives blood from the whole 
heart) than in aorta, suggesting that a significant source of circulating AM is 
produced in the myocardium (34).  AM concentration in patients with left ventricular 
dysfunction is significantly higher in pericardial fluid than in plasma (92).  Animal 
models of heart failure induced by pressure or volume overload show a significant 
increase in myocardial AM, CLR, RAMP2 and RAMP3 gene expression, suggesting 
that the entire AM signaling system is involved in regulating the response to cardiac 
stress (13, 62, 64, 95, 112).   
 Several mechanisms probably regulate the overproduction of AM in the 
stressed heart including mechanical stretch of cardiomyocytes (96), hypoxia (12, 60) 
and elevations in vasocontrictors such as angiotensin II (98) and endothelin-1 (53).  
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Up-regulation likely serves as a protective response to cardiac stress by reducing 
preload and afterload.  It may also act as a positive inotropic factor to increase 
contractility and cardiac output of the failing heart.  Additionally, AM inhibits 
myocardial remodeling by attenuating cardiomyocyte hypertrophy and reducing both 
fibroblast proliferation and extracellular matrix production (33, 66).  Finally, AM 
reduces aldosterone production (7), which is also up-regulated in heart failure.       
Therefore, AM cooperates with other natriuretic peptides to counteract the effects of 
vasoconstricting and sodium-retaining mediators such as endothelin and renin-
angiotensin-aldosterone.  Beneficial hemodynamic and neurohormonal effects of iv-
infused AM into humans with heart failure include increased cardiac output and 
natriuresis, reduction of blood pressure and left ventricular end diastolic pressure, 
and increased ejection fraction (58).    
 
Animal Models to Study AM in Heart Disease 
Since AM-/- mice are embryonic lethal (6, 83), researchers have had to focus 
their phenotyping efforts on the viable AM+/- mice as a genetic model to study the 
role of AM in cardiovascular physiology and disease.  However, in a positive way 
heterozygous mice more accurately mimic the human population, since 
polymorphisms in the AM gene may lead to similar levels of expression (47).   
AM+/- mice have been used to demonstrate protective effects on cardiac 
tissue following aortic banding and angiotensin II infusion (65, 66).  In general, these 
studies, and work from our own laboratory, have shown that AM+/- animals suffered 
greater degrees of cardiac hypertrophy and fibrosis and had a greater loss of overall 
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cardiac function.  Two other studies showed that AM gene delivery attenuates 
hypertension, cardiac remodeling and renal injury in two hypertensive rat models; 
the Dahl salt-sensitive hypertensive rat, and the deoxycorticosterone acetate-salt 
hypertensive rat (16, 114).  To date, no one has focused on the cardiomyocyte-
specific role of AM signaling in cardiac challenge.  Work presented here addresses 
this issue by using cardiomyocyte-specific Calcrl knockouts in two models; aortic 
banding and angiotensin II infusion.   
 
AM in Sepsis 
Of all the pathological conditions in which plasma levels of AM are elevated, 
sepsis ranks the highest; a whole order of magnitude higher than all other conditions 
(20).  Sepsis is defined as the clinical syndrome that results from a host’s 
uncontrolled inflammatory response to infection by activation of the innate immune 
system (49).  This self-perpetuating response involves a complex network of 
inflammatory mediators, such as tumor necrosis factor-α (TNF-α), interleukin (IL)-1β 
and IL-6 that normally function to contain and eliminate infection.  However, when 
this immune response progresses uncontrollably, the consequence is sepsis, which 
can ultimately lead to septic shock, resulting in multiple organ dysfunction, 
cardiovascular failure and death.  In fact, multiple organ failure due to severe sepsis 
and septic shock continues to be the most common cause of death in intensive care 
units (44).  It is estimated that more than 750,000 patients will develop severe sepsis 
and septic shock each year in North America, resulting in an overall mortality rate of 
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30-50% (46).  On average, it is estimated to cost $22,100 per patient with a total 
annual cost of $17 billion nationally (3).  
Sepsis is initiated by an invading organism which can either stimulate the host 
response directly, or through various components produced by the organism.  To 
initiate the host’s immune response, Gram-positive bacteria present peptidoglycan 
and lipotiechic acid, while endotoxin (lipopolysaccharide [LPS]) is the primary threat 
presented by Gram-negative bacteria.  A host response mediated by Gram-negative 
bacteria begins when LPS binds to LPS binding protein (LBP) in the plasma.  This 
LPS:LBP complex then binds to a cell membrane receptor protein, CD14.  The 
CD14:LBP:LPS complex is recognized by Toll-like receptor 4 (TLR4) which serves 
as the signal-transducing receptor for the activation of NF-κB.  The culmination of 
these signaling cascades stimulates a wide range of host immune responses, 
including the generation of complement, aggregation of platelets and the release of 
inflammatory cytokines in a number of cell types (104).  
Undoubtedly, TNF-α has been the most studied cytokine shown to play a key 
role in the pathogenesis of sepsis.  TNF-α recruits and activates macrophages, 
lymphocytes and neutrophils, and stimulates the release of other proinflammatory 
cytokines.  The degree of elevated serum TNF-α in patients with sepsis correlates 
directly with the severity of infection and indirectly with survival rate.  In addition, 
human volunteers show a systemic release of TNF-α soon after injection with 
endotoxin.  When administered to experimental animals, TNF-α  evokes a state of 
shock similar to that observed in septic shock.  Furthermore, the administration of a 
TNF-α antibody provides protection against septic shock in animals treated with 
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endotoxin, suggesting that overproduction of this cytokine is principally responsible 
for susceptibility (104).   
Sepsis and septic shock lead to a wide range of physiological consequences.  
Septic patients suffer respiratory complications that often lead to lung injury and 
pulmonary edema (23).  Kidney failure, requiring dialysis, is also frequent (100).  The 
liver also suffers alterations which can result in jaundice and changes in blood sugar 
concentrations that often require insulin treatments, even in non-diabetic patients 
(86).  Septic patients also experience a biphasic hemodynamic response.  Initially, 
an early hyperdynamic response develops, characterized by increased cardiac 
output and tissue perfusion, increased oxygen delivery and decreased vascular 
resistance.  This is followed by a later hypodynamic phase, characterized by 
reduced cardiac output and tissue perfusion, decreased oxygen delivery and 
increased vascular resistance (Table 1.1) (48).  
Administration of LPS into animals results in a dramatic elevation of plasma 
AM (8, 9, 84), with the small intestine serving as one of the primary sources of AM 
production in this response (116).  AM induction by LPS is TLR4-dependent, as C3H 
HeJ mice which have a mutated form of TLR4, show no changes in AM expression 
following LPS exposure (113).  Several factors influence AM peptide levels during 
sepsis including circulating levels of LPS (109), decrease in clearance, and 
enhanced production by multiple affected organs (24).  Additionally, expression of 
neutral endopeptidases, the key enzymes involved in AM degradation, are down-
regulated in some tissues during sepsis and this likely contributes to the observed 
elevations in AM peptide levels in septic subjects (32).   
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 Many studies have used the cecal ligation and puncture (CLP) model to study 
the action of AM in sepsis (70, 71, 101, 103, 109, 117).  Similar to what is seen in 
septic patients, animals with CLP experience a hyperdynamic cardiovascular 
response which takes place 2-10 hours after CLP, followed by a hypodynamic 
cardiovascular response which starts approximately 16 hours after CLP.  Using this 
model, plasma AM is elevated as early as 2 hours after CLP (when the 
hyperdynamic phase begins) and progressively increases up to 30 hours thereafter 
(26).  Further studies then focused on the possible role of AM in the initiation of the 
early hyperdynamic phase of sepsis.  Intravenous infusion of AM in rats mimicked 
the hyperdynamic response observed in sepsis, while administration of anti-AM 
antibodies after CLP prevented this response from occurring, demonstrating that AM 
does indeed play a key role in initiating the hyperdynamic phase in sepsis (101).  
Other animal models have also supported the role of AM as a causative factor of the 
early hyperdynamic phase (105).  It is therefore surprising that transition to the later 
hypodynamic phase occurs in the presence of high plasma AM levels.  Wang et al. 
addressed this issue in a subsequent study and showed that responsiveness to AM 
in thoracic aorta rings was not altered at 5-10 hours after CLP, but is significantly 
reduced after 20 hours of CLP (102).  It was therefore suggested that transition to 
the hypodynamic phase is due to reduced vascular responsiveness to AM in the 
later stages of sepsis.  Therapeutic interventions that would serve to maintain 
vascular responsiveness to AM might prevent or delay the progression to the 
hypodynamic phase and ultimately attenuate the severity of organ damage 
associated with sepsis.   
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 Why there is reduced vascular responsiveness to AM in sepsis is unclear, but 
there are a few possibilities.  First, as AM levels are increased following the onset of 
sepsis, there is a concomitant reduction in the amount of adrenomedullin binding 
protein-1 (AMBP-1), a protein that associates with AM to confer full biological 
activity.  Indeed, in vitro addition of AMBP-1 successfully restored vascular 
responsiveness to AM following CLP, suggesting that reduced AMBP-1 levels during 
sepsis could account for vascular AM hyporesponsiveness and the transition to the 
hypodynamic phase (115).  Another study showed that co-administration of both AM 
and AMBP-1 reduced the 10-day mortality rate in CLP-treated animals from 57% to 
7%, while treatment of either factor alone had no significant effect on survival (108).  
A second possible explanation for reduced AM vascular responsiveness lies within 
the concomitant regulation of AM receptors and RAMPs, in which a dynamic change 
in expression also occurs during sepsis (Table 1.1).  For example, Nagoshi et al. 
found that TNF-α significantly reduced the expression of Calcrl, Ramp1 and Ramp2 
in cultured human coronary artery smooth muscle cells in a time and dose-
dependent manner, thereby diminishing the AM-induced production of cAMP (59).  
Furthermore, Ono et al. examined the expression of Calcrl and Ramp1, 2, and 3 in 
several tissues from LPS-induced septic mice.  Calcrl and Ramp2 expression were 
singnificantly decreased in lungs of septic mice, whereas Ramp3 message levels 
were increased approximately 40 fold in lungs after 12 hours of LPS challenge (69). 
Using a polymicrobial model of sepsis, Ornan et al. also showed that Ramp3 
expression is elevated in lungs during the early hyperdynamic stage of sepsis, but 
not in the later hypodynamic phase (71).  Thus, combining the loss of available 
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AMBP-1 and altered expression of AM receptors probably plays a major role in the 
reduced AM vascular responsiveness observed during the septic response. 
Several publications have reported beneficial effects of exogenous AM in 
sepsis.  One group showed that AM stabilizes endothelial barrier function and 
reduces endothelial hyperpermeability, thereby preventing the development of 
pulmonary edema and improving survival in a rat model of α-toxin-induced septic 
shock (93).  Zhou et al. showed that administration of AM with AMBP-1 early after 
the onset of sepsis significantly attenuated vascular endothelial cell apoptosis (118).  
In transgenic mice overexpressing AM in their vasculature, LPS treatment induces 
less hemodynamic and inflammatory alterations, less liver damage and lower 
mortality rates than in control animals (82).   
Several studies have also demonstrated an important role for AM in 
inflammatory cytokine regulation.  AM suppresses IL-1β-induced TNF-α production 
in Swiss 3T3 cells (30).  Wu et al. demonstrated that AM and AMBP-1 both down-
regulated LPS-induced TNF-α secretion in a macrophage cell line and in rat Kupffer 
cells.  As expected, this effect was significantly enhanced when AM and AMBP-1 
were co-administered (107).  In agreement with these results, co-administration of 
AM and AMBP-1 5 hours after CLP significantly reduced plasma TNF-α, IL-1β and 
IL-6 at 20 hours after the onset of sepsis (110).  Interestingly, a separate study 
showed that AM is both anti-inflammatory and pro-inflammatory, as it down-
regulated TNF-α, but up-regulated IL-1β and IL-6 secretion from LPS-stimulated 
macrophages (106).  Discrepancies in these studies likely result from different 
experimental conditions such as cell type and dosage/time of treatments.   
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Although numerous studies have used animal models to study the role of 
administered or increased AM in septic animals, genetic studies to determine the 
consequences of reduced AM during sepsis have not yet been performed.  This 
study reports the use of mice heterozygous for the AM gene to examine the role of 
AM in regulating the inflammatory response to an LPS-induced model of sepsis.   
 
Research Presented in this Dissertation 
The overall goals of this dissertation have been to use genetically engineered 
animal models to define the receptor components essential for AM signaling in vivo 
and to determine the roles of AM signaling in two of the most clinically relevant 
conditions; cardiovascular disease and sepsis.  The work presented in chapter 2 
describes the generation and characterization of Calcrl knockout mice.  Because 
these mice die in utero at mid-gestation from various cardiovascular defects, the 
next logical step was to study the role of Calcrl in specific cell types.  Therefore, 
chapter 3 describes the generation and characterization of mice lacking Calcrl 
expression specifically in cardiomyocytes, while maintaining normal levels of 
expression in other cells.  Briefly, cardiomyocyte-specific Calcrl knockouts are born 
at the expected Mendelian ratios, survive into adulthood with no obvious defects and 
respond normally to cardiac stress induced by aortic constriction and angiotensin II 
infusion.  Chapter 4 describes the generation and characterization of Ramp2 and 
Ramp3 knockout mice.  While Ramp3 knockouts are essentially normal, mice 
lacking Ramp2 die at mid-gestation from severe generalized edema, similar to AM 
and Calcrl knockouts.  Finally, Chapter 5 presents work from another project which 
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used AM heterozygous mice to study the effects of reduced AM in a model of LPS-
induced septic shock.  Overall, this thesis elucidates the role of key genes involved 
in AM signaling in various developmental, physiological and pathological settings.    
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Figure 1.1 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.1. Fold Change in Plasma AM Levels in a Variety of Human Conditions.  
Bars indicate average fold change in circulating AM levels in various disease 
categories or conditions based on published human clinical data.  The horizontal line 
at 2.3 represents the average fold increase in plasma AM levels across all conditions 
(excluding sepsis). **, P < 0.007 between pregnancy and all other disease conditions 
(excluding sepsis). ##, P < 0.001 between normal pregnancy and pregnancy 
complications. *, P < 0.05 between sepsis and all other conditions.  Number on each 
bar indicates the number of published observations assessing plasma AM levels in 
each category. 
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Figure 1.2 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.2. The RAMP/Receptor Paradigm for AM and CGRP Signaling.  RAMPs 
convey receptor specificity by heterodimer formation with CLR in the endoplasmic 
reticulum followed by localization to the plasma membrane.  The association of CLR 
with a RAMP determines the specificity of ligand binding.  Thus, a CLR/RAMP1 
heterodimer (green) binds preferentially to CGRP, whereas association of CLR with 
either RAMP2 (dark red) or RAMP3 (light yellow) results in preferential binding to 
AM. 
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Table 1.1 
The hyperdynamic and hypodynamic phases of sepsis 
 
 
 
 
 
 
 
 
 
 
Table. 1.1. A biphasic hemodynamic response during sepsis (Upper).  Initially, an 
early hyperdynamic response develops, characterized by increased cardiac output 
and tissue perfusion, increased oxygen delivery and decreased vascular resistance. 
This is followed by a later hypodynamic phase, characterized by reduced cardiac 
output and tissue perfusion, decreased oxygen delivery and increased vascular 
resistance.  A dynamic expression pattern of AM receptor components during sepsis 
(Lower).  During the first 12 hours of the septic response, Ramp2 and Calcrl 
expression declines, while Ramp3 expression is elevated.  During the later 
hypodynamic phase of sepsis, Ramp2 and Calcrl expression are reduced by ~95% 
and Ramp3 expression begins to decrease.     
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CHAPTER 2 
HYDROPS FETALIS, CARDIOVASCULAR DEFECTS AND EMBRYONIC 
LETHALITY IN MICE LACKING THE CALCITONIN RECEPTOR–LIKE 
RECEPTOR GENE 
 
 
 
 
 
 
Abstract 
Adrenomedullin (AM) is a multi-functional peptide vasodilator that is essential 
for life.  To date, numerous in vitro studies have suggested that AM can mediate its 
biological effects through at least three different receptors. To determine the in vivo 
importance of the most likely candidate receptor, calcitonin receptor like receptor 
(CLR), a gene targeted knockout model of the Calcrl gene was generated. Mice 
heterozygous for the targeted Calcrl allele appear normal, survive to adulthood and 
reproduce. However, heterozygote matings fail to produce viable Calcrl-/- pups, 
demonstrating that Calcrl is essential for survival. Timed matings confirmed that 
Calcrl-/- embryos die between day E13.5 and E14.5 of gestation. The Calcrl-/- 
embryos exhibit extreme hydrops fetalis and cardiovascular defects, including thin 
vascular smooth muscle walls and small, disorganized hearts remarkably similar to 
the previously characterized AM-/- phenotype.  In vivo assays of cellular proliferation 
and apoptosis in the hearts and vasculature of Calcrl-/- and AM-/- embryos support 
the concept that AM signaling is a crucial mediator of cardiovascular development.  
The Calcrl gene targeted mice provide the first in vivo genetic evidence that CLR 
functions as an AM receptor during embryonic development. 
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Introduction 
 Adrenomedullin (AM) is a potent peptide vasodilator that has been implicated 
in a wide variety of normal physiological processes including embryonic 
development (5), natriuresis (36), regulation of salt and water appetite (41, 48), 
cellular proliferation (7, 17, 49, 54), angiogenesis (11, 26) and anti-microbial defense 
(3).  During many cardiovascular stresses such as pregnancy, septic shock, 
hypertension and renal failure, plasma levels of AM are dramatically elevated and 
thought to provide a protective homeostatic response, diminishing adverse tissue 
remodeling and fibrosis associated with cardiovascular stress (16, 35, 42-44). 
Our previous studies using a genetically engineered AM knockout mouse 
model have demonstrated an essential role for the AM gene in the development of 
cardiovascular tissues (5).  Mice lacking the AM gene suffer from extreme hydrops 
fetalis and die at mid-gestation.  The most obvious phenotype of AM-/- embryos is 
severe interstitial fluid accumulation and generalized edema.  Closer evaluation of 
the AM-/- embryos also revealed developmental cardiovascular defects that include 
thin vascular smooth muscle walls and smaller hearts with thin compact zones and 
disorganized trabeculae (5).  However, the cellular mechanisms underlying these 
embryonic cardiovascular defects remain unclear. 
Since the identification of the AM peptide over 10 years ago (27), three 
putative receptors have been identified and suggested to mediate the biological 
effects of AM based on their ability to bind the peptide and elicit a cAMP response to 
AM treatment in vitro.  L1, originally cloned as an orphan receptor (10, 15), binds to 
AM with a Kd of 8.2 X 10-9 M and can mediate a cAMP response to AM when 
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expressed in COS-7 cells (21).  It is co-expressed with the AM peptide in most 
tissues (21) but is found at significantly lower levels than the two other putative AM 
receptors in rat neonatal cardiac myocytes (4).  A second receptor, RDC-1, was 
originally identified as a receptor for the AM-related peptide, calcitonin gene related 
peptide (CGRP), but also binds to AM with a Kd of 1.9 X 10-7 M and mediates a 
dose-dependant cAMP response to AM when expressed in COS-7 cells (22).  A third 
receptor, commonly referred to as the calcitonin receptor-like receptor (CRLR), now 
usually referred to as the calcitonin-like receptor (CLR), was cloned independently 
by several groups (1, 14) but subsequently failed to produce consistent expression, 
binding, and functional results with CGRP or AM (1, 9, 12, 14, 45).  Several recent 
studies have also failed to support the role of either L1 or RDC-1 as AM receptors 
(19, 25, 32, 39).  
Most recently, the identification of a novel class of G-protein coupled receptor 
(GPCR) activity modifying proteins (RAMPs) and their association with CLR has 
helped to elucidate the most likely mechanism through which the AM peptide 
transduces its signal.  Briefly, McLatchie et al. demonstrated that association with 
RAMP1 made CLR bind preferentially to CGRP while association of CLR with 
RAMP2 or RAMP3 made it bind to AM (39).  This novel role of the RAMPs in GPCR 
cell signaling implies that the spatial and temporal expression of RAMP proteins 
dictates the presence and function of CLR as an AM receptor or a CGRP receptor 
and helps clarify some of the past confusion regarding AM signaling.  However, no in 
vivo genetic studies to substantiate the identity of CLR as a functional AM receptor 
have been performed despite the great interest in the role of the peptide during 
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embryonic development and the possibility that modulating AM function might prove 
valuable for the treatment of cardiovascular disease. 
In this paper, we used gene targeting in embryonic stem cells to generate and 
characterize mice that are deficient for the Calcrl gene, which encodes CLR.  We 
find that although Calcrl+/- mice have no overt phenotypic defects, the Calcrl gene is 
essential for survival since no Calcrl-/- pups were ever born from heterozygote 
matings.  Significantly, the embryonic lethal phenotype of the Calcrl-/- mice is 
remarkably similar to the phenotype we previously observed for AM-/- mice, including 
hydrops fetalis and developmental abnormalities in cardiovascular tissues (5).  More 
detailed characterization of the growth properties of Calcrl-/- and AM-/- vasculature 
and hearts has further confirmed an essential role for this signaling pathway in the 
growth and proliferation of the embryonic cardiovascular system. 
 
Materials and Methods 
Construction of the Calcrl Targeting Vector 
To generate a Calcrl knockout targeting vector, a 129S6/SvEv genomic library 
was screened for phage clones containing the 5’ portion of the Calcrl gene.  A 
genomic clone consisting of approximately 11.5 kb and containing exons 3 through 9 
of the Calcrl gene was used to isolate and clone a 5’ short arm and 3’ long arm of 
homology into a gene targeting vector (osdupdel) which contains multiple cloning 
sites flanking a PGK-neomycin cassette and also includes a HSV-thymidine kinase 
cassette.  The 5.0 kb long arm of homology, which includes exons 7, 8 and 9, was 
isolated and subcloned using Hind III and Xho I restriction sites endogenous to the 
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gene locus.  The 1.3 kb short arm of homology containing exon 4 was generated by 
PCR using the genomic phage clone as a template and oligo sequences that 
correspond to genomic sequences (5’-GGAAATTAGATTTTCAAGGGGTG-3’ and 5’-
GGCCTTTAAACTGTGAGCAAAG-3’).  The short arm was inserted into the targeting 
vector by blunt ligation and the final targeting vector was linearized with Not I (Figure 
2.1a). 
 
Generation of Calcrl+/- ES Cells and Calcrl-/- mice 
Standard gene targeting methods were utilized to generate ES cells and mice 
lacking CLR (30).  Briefly, 129S6/SvEv-TC-1 embryonic stem cells were 
electroporated with the linearized targeting vector shown in Fig. 2.1a.  After applying 
positive (G418) and negative (ganciclovir) selection, a positive ES cell clone was 
identified by PCR from over 800 selected clones.  For PCR-based screening of 
targeted ES cells, we used 3 primers depicted in Fig. 2.1a; primer 1: 5’-
GTGATTTGAGTCTGGAGA-3’; primer 3: 5’-GAAATGTGCTGTATGTTCAAG-3’; 
primer 4: 5’-TGGCGGACCGCTATCAGGAC-3’.  Male chimeric mice that transmitted 
the targeted allele were bred to 129S6/SvEv females in order to establish an 
isogenic colony.  To isolate Calcrl-/- embryos, heterozygote Calcrl+/- breedings were 
established and the day of the vaginal plug was considered embryonic day 0.5 
(E0.5).  For routine PCR-based genotyping of mice, we used a three primer strategy 
in which primer 2: 5’-GCTATGCTTTGTTTTCTGACA-3’ and primer 3 amplify the 
wildtype allele while primer 2 and primer 4 amplify the targeted allele. 
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Generation of AM-/- mice 
 The generation, genotyping and characterization of mice with a targeted 
deletion of the AM gene have been previously been described (5). 
 
Gene Expression Analysis 
Calcrl gene expression was analyzed by real-time quantitative reverse 
transcription-PCR with the Mx3000P Real-Time PCR machine from Stratagene. 
Primers for Calcrl amplification were 5’-CAAGATCATGACGGCTCAATA-3’ and 5’-
CGTCATTCCAGCATAGCCAT-3’. The probe sequence for Calcrl detection was 5’-
FAM-CATGCAGGACCCCATTCAACAAGCAT-TAMRA-3’. β-actin served as an 
internal control for all reactions. The primers used for β-actin amplification were 5’-
CTGCCTGACGGCCAAGTC-3’ and 5’CAAGAAGGAAGGCTGGAAAAGA-3’. The 
probe sequence for β-actin detection was 5’-TET-
CACTATTGGCAACGAGCGGTTCCG-TAMRA-3’. RNA was isolated from E13.5 
embryos with TRIzol Reagent (GIBCO/BRL) and subsequently DNase treated and 
purified with an RNeasy Mini Kit (Qiagen). 200 ng of total RNA was used in each 
reaction. The ΔΔCt method (33) was used to determine the relative levels of Calcrl 
expression and shown as a percentage of wild type. All assays were repeated three 
times, each with duplicates. 
 
Histology 
For histological analyses, embryos were dissected from the uterus at the 
desired stage of gestation, fixed in 4% paraformaldehyde (PFA), dehydrated, and 
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embedded in paraffin wax. 5 µm sections were mounted on slides for subsequent 
Hematoxylin & Eosin (H&E), anti-α-SMA, BrdU or TUNEL staining.  
 
Anti-PECAM Staining 
Tissues were fixed in 4% PFA in PBS overnight. Tissues were then 
cryoprotected with 30% sucrose in PBS overnight, embedded in OCT (Tissue-Tek) 
and cryosectioned at 10µm. Sections were rehydrated in PBS, quenched in 50mM 
NH4Cl in PBS, permeabilized with 0.2% Triton/PBS and blocked in 3% BSA/1% FBS 
in PBS. Sections were incubated with anti-PECAM-1 (BD Pharmingen, cat# 550274) 
overnight at 4 degrees. After washing with TBST and PBS, sections were incubated 
with a Cy3 labeled donkey anti-rat secondary antibody (Jackson ImmunoResearch, 
code# 712-165-150) for 2 hours at room temperature. Sections were then washed 
with TBST and PBS and mounted for imaging. Images were acquired on a Nikon 
E800 microscope with a Hammamatsu ORCA-ER CCD camera with Metamorph 
software (Molecular Devices Corp.) and processed in Photoshop.  
 
Anti-SMαA Staining 
Paraffin sections were deparaffinized and rehydrated and subsequently 
placed in 0.3% H2O2 in methanol for 15 minutes to block endogenous peroxidase 
activity. Sections were then rinsed in dH2O and permeabilized in 3% BSA with 0.2% 
Triton x100 in PBS. After washing in PBS, specimens were incubated with anti-
smooth muscle α actin (Sigma, cat# A2547) antibody for 1 hour at room 
temperature. Sections were then washed with TBST and PBS and incubated with an 
 43
HRP-labeled goat anti-mouse secondary antibody (Upstate, cat# 12-349) for 90 
minutes at room temperature. After washing with TBST and PBS, peroxidase 
reaction was visualized with diaminobenzidine/hydrogen peroxide (Pierce, product# 
34065), counterstained with 1% methyl green and mounted for imaging. Images 
were acquired on a Nikon FXA microscope and processed with Photoshop.  
 
Cell Proliferation Assay 
To label proliferating cells, pregnant mice received a single intraperitoneal 
injection of BrdU (Sigma B9285), using 100 mg BrdU per kg of body weight. One 
hour after injection, pregnant females were euthanized by cervical dislocation and 
embryos were prepared for histology as described above. BrdU was detected using 
the BrdU Staining kit from Zymed (#93-3943).  Images were collected using a Leica 
MZ 16 FA dissecting microscope and the number of BrdU positive cells was 
quantified as the number of BrdU positive cells per area using Image J software. 
 
TUNEL Cell Death Assay 
Apoptotic cells were identified in 5 µm paraffin embedded sections using the 
ApopTag Fluorescein In Situ apoptosis detection kit (Chemicon) according to the 
manufacturer’s protocol.  Images were acquired on a Nikon E800 microscope with a 
Hammamatsu ORCA-ER CCD camera with Metamorph software (Molecular Devices 
Corp.) and processed in Photoshop. 
 
Statistics 
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Statistical analyses were performed with a Student’s t test with unequal 
variance.     
 
Experimental Animals 
All experiments were approved by the Institutional Animal Care and Use 
Committee of the University of North Carolina at Chapel Hill.  
 
Results 
Generation of mice lacking the Calcrl gene 
Mice in which exons 5 and 6 of the Calcrl gene were deleted by homologous 
recombination were generated using the targeting strategy shown in Figure 2.1a. 
The disrupted allele, which lacks the Calcrl translation start site, was detected by 
Southern blot analysis using a genomic probe fragment located outside the areas of 
homology (Fig. 2.1b) and by PCR (Fig. 2.1c). To confirm that the gene targeting 
effectively disrupted transcription of the Calcrl gene, quantitative reverse 
transcription-PCR for Calcrl RNA was performed on total RNA isolated from whole 
embryos. As expected, Calcrl+/- embryos expressed approximately half of wildtype 
Calcrl RNA levels (38.2%, p< 0.0001 vs. wildtype) while Calcrl-/- embryos had no 
detectable levels of Calcrl RNA, thus confirming complete loss of Calcrl expression 
in knockout embryos (Fig. 2.1d). 
 
Calcrl-/- mice die at mid-gestation with extreme hydrops fetalis 
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 Mice heterozygous for the targeted Calcrl allele appeared normal at birth, 
survived to adulthood and reproduced.  However, breeding Calcrl+/- mice failed to 
produce any viable Calcrl-/- offspring, demonstrating that the Calcrl gene is essential 
for survival. Timed matings between Calcrl+/- mice revealed that, although the 
homozygous null Calcrl-/- embryos were indistinguishable from their wildtype 
littermates at embryonic day 11.5 (E11.5, data not shown), by E12.5 the Calcrl-/- 
embryos were readily distinguishable from their Calcrl+/+ and Calcrl+/- littermates by 
the presence of generalized, interstitial edema (Fig. 2.2a).  The edema formation 
rapidly progressed so that by day E13.5 all Calcrl-/- embryos suffered from extreme 
hydrops fetalis (Fig. 2.2b) with an associated in utero mortality rate of approximately 
50%.  By E14.5 all Calcrl-/- embryos examined were dead.  We note that our previous 
studies with AM-/- mice (5) revealed a similar type of generalized edema, however 
the onset of the edema occurred 24 hours later in gestation at E13.5.  
Histological examination of Calcrl-/- embryos at E13.5 revealed distended skin 
due to fluid accumulation in the interstitial space, and a distended fluid-filled thoracic 
cavity (arrows in Fig. 2.2d, see also asterisk in Figs. 2.3e and 2.3f).  We did not 
observe any significant hemorrhage in the hydropic Calcrl-/- embryos, suggesting that 
the blood vascular system remained structurally intact. 
 
Calcrl-/- embryos have thin vascular smooth muscle walls 
Numerous reports generated from in vitro experiments have shown that AM 
has either a negative or positive effect on vascular smooth muscle cell proliferation 
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(17, 20, 49, 55). Therefore, we used our in vivo genetic model to determine the role 
of AM signaling in the vascular smooth muscle cell layer of the developing aorta.   
Histological comparison of the descending aorta revealed significantly fewer 
vascular smooth muscle cells in Calcrl-/- knockout embryos compared to their 
wildtype littermates at gestational days E12.5 and E13.5 (Figs 2.3b, 2.3c, 2.3e and 
2.3f). This difference in vascular muscle wall thickness between Calcrl-/- and wildtype 
littermates was not apparent one day earlier in gestation at E11.5 (Figs 2.3a and 
2.3d).  
The percentage of BrdU positive cells in the vascular smooth muscle cell 
layer of the descending aorta of E12.5 embryos was quantified to determine the 
effects of CLR deletion on cellular proliferation (Fig. 2.3g).  We found a significant 
reduction in the percentage of BrdU positive cells in the vessel walls of Calcrl-/- 
embryos when compared to wildtype littermates (17.67 +/- 1.17 for Calcrl-/- versus 
27.64 +/- 2.01 for wildtype, p≤0.005).  
To establish that the reduction in vascular smooth muscle wall thickness in 
Calcrl-/- embryos was not affected by abnormal smooth muscle cell differentiation or 
defects in endothelial patterning, we performed immunohistochemistry using 
antibodies against a smooth muscle marker, α-smooth muscle actin (α-SMA) and an 
endothelial marker, PECAM.   As shown in Figures 2.3h and 2.3j, the aortic vascular 
smooth muscle cells of Calcrl-/- mice, like their wildtype counterparts, are positive for 
α-SMA, demonstrating normal vascular smooth muscle cell differentiation.  Anti-
PECAM staining also revealed a complete and well-formed endothelial lining in the 
aorta, demonstrating that endothelial tube formation and the final patterning of the 
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endothelial lining of the large vessels is unaffected in the major arteries of Calcrl-/- 
mice compared to wildtype embryos (Fig. 2.3i and 2.3k).     
 
Calcrl-/- embryos have small and disorganized hearts 
Transverse sections through the embryonic hearts at E11.5 revealed no 
obvious differences between Calcrl-/- and wildtype mice (Fig. 2.4a and 2.4d).  
However, by E12.5 (Fig. 2.4b and 2.4e) the Calcrl-/- embryos had significantly 
smaller hearts than their wildtype littermates.  By E13.5 (Fig. 2.4c and 2.4f) the 
overall heart size of the Calcrl-/- embryonic heart was approximately two thirds the 
size of the wildtype littermate heart.  The atria, mitral and tricuspid valves, 
endocardial cushion and ventricular septum appeared normal at all gestational ages 
(Fig. 2.4).  Higher magnification of the left ventricle showed that at E12.5 and E13.5 
the compact zone of Calcrl-/- hearts appeared thin and discontinuous (Fig 2.5 f-h) 
compared to wildtype controls (Fig 2.5 b-d).  The myocardium also had a generally 
disorganized structure and the chamber appeared crowded (Fig. 2.5g and 2.5h).  
Immunohistochemical staining to characterize the presence and location of 
cardiomyocytes (α-actinin), endocardial cells (PECAM) and proliferating 
myofibroblasts (α- smooth muscle actin) revealed no obvious abnormalities in Calcrl-
/-  hearts compared to wildtype control hearts (data not shown). 
 
Decreased cellular proliferation in Calcrl-/-  and AM-/- hearts 
Based on our observation of smaller heart size and the fact that both AM and 
CGRP peptides have been previously shown to mediate cell growth, proliferation 
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and survival in a variety of different tissues (2, 17, 37, 57), we evaluated the extent 
of cell proliferation and apoptosis in developing Calcrl-/- and AM-/- hearts at various 
gestational stages.  Using the incorporation of BrdU as a measure of cell 
proliferation, we found no significant difference in the amount of proliferation in the 
ventricles of E11.5 Calcrl-/- embryos compared to wildtype littermates (101 +/- 3.25  
for Calcrl-/- versus 101.6 +/- 4.14 for wildtype , p=0.927, Fig. 2.6a). In contrast, by 
E12.5 we found a significant reduction in the total number of BrdU positive cells in 
the ventricles of Calcrl-/- embryos compared to wildtype littermates (80.45 +/- 6.21 for 
Calcrl-/- versus 111.66 +/- 4.29 for wildtype, p≤0.005, Fig. 2.6a).  Similarly, E13.5 AM-
/- embryos showed a significant reduction in BrdU positive cells in the ventricles 
when compared to wildtype littermate controls (58.12 +/- 2.51 for AM-/- and 82.52 +/- 
8.87 for wildtype, p<0.05, Fig. 2.6b). 
 
Increased apoptosis in Calcrl-/-  and AM-/- hearts 
Staining for apoptotic cells by TUNEL also revealed remarkable differences 
between the development of Calcrl-/- and AM-/- hearts compared to wildtype 
littermates.  At E11.5 we found no obvious differences in the overall number of 
apoptotic cells which are normally present in the developing endocardial cushion, 
ventricular septum and ventricular apex of the heart (data not shown).  Comparison 
of TUNEL staining in other organs of Calcrl-/- and wildtype littermates at E13.5 also 
revealed no significant difference in the number of apoptotic cells in the lung, dorsal 
root ganglia or the central canal of the spinal cord and only a slight increase in the 
liver (data not shown).  However, by E13.5 we found a marked increase 
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(approximately 6 times more than wildtype) in the number of TUNEL-positive cells 
throughout the hearts, particularly in the ventricular apex, endocardial cushion and 
septum of Calcrl-/- and AM-/- embryos compared to control littermates (Fig. 2.7). 
 
Discussion 
We used gene targeting in embryonic stem cells to generate and characterize 
mice that are deficient for the gene that encodes for one of the three putative AM 
receptors, CLR.  Our most significant finding is that the Calcrl gene is essential for 
survival since Calcrl-/- mice die in utero at mid-gestation.  Significantly, the embryonic 
lethal phenotype of the Calcrl-/- mice is almost indistinguishable from the phenotype 
we previously characterized for mice carrying a targeted deletion of the AM peptide 
(5).  These shared phenotypes include severe generalized edema, developmental 
abnormalities in cardiovascular tissues that consist of reduced vascular smooth 
muscle cell development in the large arteries, and a small overall heart size with a 
thin and discontinuous compact zone.  Although biochemical studies have identified 
at least three putative receptors for AM peptide signaling, the remarkable similarity 
between the phenotypes observed for these two knockout models provides 
compelling genetic and in vivo evidence that CLR is the primary receptor through 
which AM peptide acts during embryonic development.  However, our results do not 
exclude the possibility that L1 and/or RDC1 also contribute to the function of AM at 
the same stage of life. 
Another recent description of a gene targeted mouse model by Czyzyk et al. 
also provides additional compelling support for our conclusion that disruption of AM 
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signaling during embryonic development results in the consistent phenotype we 
describe.   In their study, the authors show that deletion of the gene that encodes for 
peptidylglycine alpha-amidating monooxygenase (PAM), an enzyme that serves as 
the sole source of peptide amidation in the mouse, results in embryonic lethality, 
edema and cardiovascular defects that phenocopy the AM and Calcrl knockout 
models.  Since amidation of AM peptide is required for its biological activity, the 
authors conclude that lack of amidation results in loss of AM function, presumably by 
reducing its ability to bind to its receptor(s), with a resulting phenotype that is 
strikingly similar to that seen in AM knockout embryos.  Because several mouse 
models for deletion of genes that encode for other amidated peptides exist in which 
similar phenotypes are not observed, it is likely that inactivation of AM signaling in 
PAM mutants is the primary cause of the observed phenotype (8).  Taken together, 
the description of a similar phenotype for three separate knockout mouse models 
demonstrates that abnormal cardiovascular development and generalized edema 
can be expected when AM signaling is disrupted during embryonic development. 
The only significant difference we found between the CLR knockout and AM 
peptide knockout models is the timing of phenotypic onset: the edema and 
cardiovascular defects appeared 24 hours earlier in the Calcrl-/-  knockout embryos 
(E12.5) than in the AM-/-  knockout embryos (E13.5) (5).  Given the recent finding 
that RAMP proteins determine the ligand binding affinity for CLR to either the CGRP 
peptide or the AM peptide, the most likely explanation for the difference in time of 
phenotypic onset is that Calcrl-/- mice have lost the ability to transduce signal for both 
AM and CGRP peptides by virtue of losing a shared GPCR.  The AM knockout mice 
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may survive a while longer because they still have CGRP peptide signaling which is 
probably absent in the more severely affected Calcrl-/- mice.  However, it is clear that 
CGRP signaling is not essential for survival since CGRP peptide knockout mice 
develop normally and survive to adulthood with only modest defects in blood 
pressure regulation and sympathetic nervous activity (13, 34, 47, 58).  In addition, 
our experiments do not rule out the possibility that CLR, perhaps in association with 
different RAMP proteins, may bind and mediate the function of other unidentified 
peptide ligands.  Thus, the precise reason for the difference in gestational 
phenotypic onset between the Calcrl-/- and AM-/- mice remains an ongoing area of 
investigation. 
 The cause of edema in the Calcrl-/- and AM-/- mice also requires further 
investigation.  Embryonic lethality due to cardiovascular defects in genetically 
engineered murine models is sometimes associated with embryonic edema (6, 31, 
38, 46, 50). However, the edema is usually mild, localized to the subcutaneous 
region and accompanied by hemorrhage and/or a blood-filled liver.  In contrast, two 
recent reports demonstrate that generalized, interstitial edema similar to that seen in 
the Calcrl-/- and AM-/-  knockouts is caused by abnormalities in or failure of lymphatic 
vessel development (23, 56). Given the role of AM as an angiogenic factor, it is 
possible that a lack of AM signaling by genetic deletion of either the AM peptide or 
the CLR receptor results in lymphatic defects that cause severe and generalized 
hydrops fetalis. Current data is not yet sufficient to conclude the cause of edema in 
our mice. 
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 It is well appreciated that AM peptide can differentially affect the growth 
properties of various cell types (2, 17, 37, 57).  For example, while AM can inhibit 
apoptosis of cardiomyocytes (24, 51), it can also promote endothelial and vascular 
smooth muscle cell proliferation (17, 40).  The effects of enhanced or reduced AM 
signaling on cells of the cardiovascular system are of particular interest since AM 
peptide levels dramatically increase in patients suffering from many cardiovascular 
conditions, including congestive heart failure (18), hypertension (29), myocardial 
infarction (28) and cardiac hypertrophy (52), and may provide protection against the 
development of adverse tissue remodeling and fibrosis associated with 
cardiovascular stress (43, 44, 53).  Our data provide the first in vivo, genetic 
evidence that the AM and Calcrl genes allow transduction of essential signals during 
development that positively mediate the growth and proliferation of vascular smooth 
muscle cells and cardiac cells while concurrently negatively influencing cardiac cell 
apoptosis.   
In conclusion, our studies using a genetically engineered knockout model for 
the Calcrl gene demonstrate an essential role for the CLR GPCR during embryonic 
cardiovascular development. The remarkable similarity between the Calcrl-/- and  
AM-/- embryonic phenotypes leads us to conclude that CLR is the predominant 
receptor mediating AM signaling during development.  
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Figure 2.1 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
FIG. 2.1. Generation of Calcrl-/- animals by homologous recombination. (a) 
Strategy to disrupt the Calcrl gene. (Top) Endogenous wildtype allele. (Middle) 
Targeting vector. (Bottom) Targeted allele following homologous recombination. 
Primer locations for PCR (p1, p2, p3, p4) are shown with arrows. The location of the 
probe used for the Southern-based detection strategy is indicated by a labeled line 
(PROBE).  The targeting vector plasmid sequence is indicated by a thin wavy line.   
Restriction sites: H, HindIII; X, XhoI. The initiator methionine and terminator codons 
are indicated as Met and STOP. (b) Detection of targeted ES cells by Southern blot 
analysis. Digestion of genomic DNA with HindIII results in a 9.0 kb fragment for the 
WT allele and a 7.4 kb fragment for the targeted allele when probed with the 
fragment depicted in a. (c) Primers depicted in a were used to amplify genomic DNA 
from embryos. (d) Measurement of Calcrl expression from total RNA extracts by 
real-time quantitative reverse transcription PCR. The relative quantity of Calcrl RNA 
in Calcrl+/- and Calcrl-/- embryos is represented as a percentage of total Calcrl RNA 
in WT embryos. Error bars represent SEM. 
 
 
 
 
 54
Figure 2.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG. 2.2. Calcrl-/- embryos have massive generalized edema. (a) 
Generalized edema is observed throughout the entire body in Calcrl-/- 
embryos at E12.5. (b) By E13.5 the generalized edema in Calcrl-/- embryos 
has progressed to severe hydrops fetalis. (c and d) H&E stain of transverse 
sections through E13.5 WT (c) and Calcrl-/- (d) embryos. The thoracic cavity 
and interstitial tissues are filled with fluid and distended (see arrows in d, X1). 
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Figure 2.3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG. 2.3. Calcrl-/- embryos have thin arterial walls due to reduction in 
vascular smooth muscle cell proliferation. Transverse sections through 
the descending aorta of wildtype and Calcrl-/- embryos at E11.5, 12.5 and 
13.5 were stained with H&E (a-f). The thickness of the vessel walls at E11.5 
is similar in wildtype and Calcrl-/- sections.  However, by E12.5 and E13.5 the 
vascular walls are thinner in Calcrl-/- mice (approximately 3 cells thick) when 
compared to wildtype controls (approximately 6 cells thick). The asterisk 
denotes the accumulation of interstitial edema in Calcrl-/- embryos. The 
percentage of proliferating, BrdU-positive cells in the aortic wall of Calcrl-/- 
mice is significantly less than in wildtype controls (g). Vascular smooth 
muscle cells in wildtype and Calcrl-/- aortas stain positive for α-SMA (h & j). 
Anti-PECAM staining shows that wildtype and Calcrl-/- aortas have normal 
endothelial patterning (i and k).  a, aorta (X10). Scale bar, 50 µm. 
 
 
 
 
 56
Figure 2.4 
 
 
 
 
 
 
 
 
 
 
 
 
FIG. 2.4. Calcrl-/- embryos have developmental heart defects. Transverse 
sections through the hearts of wildtype and Calcrl-/- embryos at E11.5, 12.5 and 13.5 
were stained with H&E. At E11.5 (a and d) the overall heart size is similar in both 
wildtype and Calcrl-/- embryos. At E12.5 (b and e), the overall heart size in the Calcrl-
/- embryo is smaller than that of its wildtype littermate. At E13.5 (c and f), the overall 
heart size in the Calcrl-/- embryo is approximately two thirds the size of its wildtype 
littermate. c, endocardial cushion; s, septum; t, tricuspid valve; m, mitral valve; rv, 
right ventricle; lv, left ventricle; ch, chamber; cz, compact zone (X4). Scale bar, 200 
µm. 
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Figure 2.5 
 
 
 
 
 
 
 
 
 
 
FIG. 2.5. Calcrl-/- embryos show thin and disorganized compact zones of the 
heart. Transverse sections through the hearts of wildtype and Calcrl-/- embryos at 
E11.5, 12.5 and 13.5 were stained with H&E. The compact zone in wildtype and 
Calcrl-/- embryos at E11.5 (a and e) and E12.5 (b and f) is similar in thickness and 
cellular organization. At E13.5 (c and g) the compact zone is thinner in the Calcrl-/- 
embryo. Higher magnification (d and h) reveals a discontinuous and convoluted 
organization of the compact zone in the Calcrl-/- section. ch, chamber; cz, compact 
zone (a, b, c, e, f, g X10 and d, g X20). Scale bar for X10 images is 100 µm; for X20 
images scale bar is 50 µm.  
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Figure 2.6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG. 2.6. Calcrl-/- and AM-/- embryos have defects in cardiac cell proliferation. 
The proliferation index of cardiac cells was determined as the number of BrdU 
positive cells per total area in transverse heart sections. (a) No significant difference 
was found between wildtype and Calcrl-/- embryos at E11.5. However, at E12.5 the 
proliferation index was significantly lower in Calcrl-/- embryos when compared to 
wildtype controls. (b) The proliferation index of AM-/- embryos at E13.5 is significantly 
lower than wildtype littermates.  
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Figure 2.7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG. 2.7. Calcrl-/- and AM-/- embryos at E13.5 have increased levels of cardiac 
apoptosis. Typical pictures of TUNEL stained transverse sections. (a) The number 
of TUNEL positive cells is greater in Calcrl-/- and AM-/- hearts (b and d, respectively) 
when compared to wildtype littermates (a and c). 
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CHAPTER 3 
CARDIOMYOCYTE-SPECIFIC DELETION OF THE CALCITONIN RECEPTOR-LIKE 
RECEPTOR (CALCRL) HAS NO EFFECT ON CARDIAC DEVELOPMENT OR FUNCTION
Abstract 
Adrenomedullin (AM) is a dynamic regulatory peptide that is expressed and 
secreted by several cell types including vascular smooth muscle cells, endothelial 
cells and cardiomyocytes.  AM signaling is mediated by a 7-transmembrane G-
protein coupled receptor called the calcitonin receptor-like receptor (CLR, protein; 
Calcrl, gene).  Multiple animal and human studies have focused on the role of AM in 
cardiovascular physiology and disease.  The consistent observation is that AM 
serves a protective role in heart disease.  However, our current understanding of AM 
physiology is incomplete due to several factors, including embryonic lethality of AM 
and Calcrl knockout mice and a broad expression pattern of AM and genes involved 
in its signaling.  To enhance our understanding of AM signaling in cardiac physiology 
and disease, we deleted the Calcrl gene specifically in cardiomyocytes by crossing 
“floxed” Calcrl mice to mice expressing Cre-recombinase under the control of the 
alpha-myosin heavy chain promoter.  Cardiomyocyte-specific Calcrl knockouts were 
born at the expected Mendelian ratios and had normal cardiac structure and 
function.  The hypertrophic response to aortic constriction and angiotensin II infusion 
was also similar in controls and knockouts.  Furthermore, cardiomyocyte contractility 
was not altered in knockout cells.  Conclusively, this study shows that genetic 
deletion of the AM receptor, Calcrl, specifically in cardiomyocytes has no effect on 
cardiac development, function, or response to different disease models.  It is thus 
likely that the cardioprotective effects of AM are mediated through another cell type, 
such as endothelial cells and/or vascular smooth muscle cells.         
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Introduction 
Adrenomedullin (AM) is a dynamic peptide that is expressed and secreted 
from various tissues of the cardiovascular system including the kidneys, heart, lung 
and blood vessels (11).  The receptor for AM, which is co-expressed in the same 
cells that secrete AM, is a G-protein coupled receptor called the calcitonin receptor-
like receptor (Calcrl, gene; CLR, protein) (19, 25).  AM peptide and the expression of 
its receptor are significantly elevated in several conditions such as normal 
pregnancy (10, 43), cardiovascular disease (17, 18, 22, 30, 31, 33, 45) and cancer 
(12, 40).  It is therefore likely that AM is a key factor in regulating the physiological 
processes performed by the cardiovascular system in both normal and 
pathophysiological situations.  
A number of reports, from both animal and human studies, have 
demonstrated a protective role for AM in heart disease.  We recently demonstrated 
that mice with 50% expression of AM (AM+/-) develop greater degrees of cardiac 
hypertrophy and renal damage in a genetic model of renin-induced hypertension (4).   
A study by Niu et al. also used AM+/- mice to show that endogenous AM is protective 
against cardiac hypertrophy and fibrosis induced by aortic constriction or Ang II 
infusion (35).  Furthermore, intravenous infusion of AM into patients who had 
recently suffered a myocardial infarction revealed several beneficial effects including 
decreased left ventricular systolic pressure, increased myocardial contractility, 
increased cardiac index and improved left ventricular relaxation (27, 28). 
There are many mechanisms by which AM may exert its cardioprotective 
effects.  Because AM acts as a potent vasodilator, which ultimately reduces 
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peripheral resistance, many of its beneficial effects on the heart could be secondary 
to reduced afterload (23).  However, several reports have also demonstrated direct 
effects of AM on cardiomyocyte function and growth.  Whether or not AM directly 
affects myocardial contractility is still controversial.  Some groups have observed a 
negative, positive or no inotropic effect on myocardial contractility (13, 14, 41, 42).  
One group even found a dual inotropic effect, due to a switch from Gs to Gi coupling 
of the receptor after prolonged (30 minutes) exposure to AM (26).  These 
contradictory results may be due to different experimental conditions and assay 
readouts.  Some studies base their results on developed tension in muscle, while 
others measure individual cell shortening and/or intracellular Ca2+ levels in isolated 
cells.  In addition, model species, amount of AM peptide used for treatment and 
method of muscle stimulation have varied across studies. 
The effects of AM on cardiomyocyte growth and apoptosis have been well 
documented.  Previous reports from our lab show that mice lacking either the AM or 
Calcrl gene develop small hearts and have defects in myocardial proliferation and 
apoptosis (9).  Tokudome et al. demonstrated that AM inhibits doxorubicin-induced 
apoptosis in cardiomyocytes via a cAMP dependent mechanism (44).  Two other 
reports also showed that AM attenuates myocardial apoptosis following ischemia-
reperfusion in the rat via activation of the Akt-GSK pathway and reduced caspase-3 
activation (36, 47).  Finally, AM prevents cardiac hypertrophy by inhibiting protein 
synthesis in cardiomyocytes (46).     
Our previous studies using genetically engineered knockout mouse models 
for both the AM and Calcrl genes, demonstrated that AM signaling is essential for life 
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(5, 9).  Mice lacking either gene suffer from extreme hydrops fetalis (generalized 
edema) due to abnormal development of the lymphatic vascular system (JCI in 
press).  These mice eventually die at mid-gestation with multiple cardiovascular 
defects.  Because these phenotypes are complex and likely interrelated, it becomes 
challenging to determine the cell autonomous cause of death in global knockouts.  In 
addition, the gestational lethality of AM and Calcrl knockout mice precludes their use 
for investigating the potential cardioprotective mechanism of AM signaling in adult 
animals.  Therefore, we have addressed the role of AM signaling in cardiac 
development and physiology by generating a mouse model that lacks Calcrl 
expression specifically in cardiomyocytes, while maintaining normal expression 
levels in other cell types.   
  
Materials and Methods 
Experimental Animals 
The generation of CalcrlFlox/Flox mice has been previously reported (JCI in 
press).  Cardiomyocyte-specific Calcrl null mice were generated by crossing Calcrl+/- 
mice to αMHCCre+ mice (1).  The resulting Calcrl+/-;αMHCCre+ animals were then 
bred to CalcrlFlox/Flox mice, resulting in the experimental animals used for this study.  
Experiments were performed with littermates of Calcrl+/LoxP;αMHCCre+ for controls 
and Calcrl-/LoxP;αMHCCre+ for knockouts.  All mice used for this study were males 
and were between 12 to 15 weeks of age.   
PCR detection of the αMHCCre transgene was performed using previously 
described primers (1).  Genotyping for the Calcrl allele was performed with the same 
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three-primer strategy used for our original Calcrl gene targeted mice (9).  The 
recombined Calcrl allele, produced by Cre-mediated recombination of the Calcrl 
floxed allele, was detected using a forward 5’-GCGGAGCATATTCAATCACAAG-3’ 
and reverse 5’-TGATGCCAGCTAACATAGAATTGG-3’ primer set.  
All experiments were approved by the Institutional Animal Care and Use 
Committee of the University of North Carolina at Chapel Hill. 
 
Aortic Banding 
Left ventricular pressure overload was induced for 28 days by transverse 
aortic constriction as previously described (39).  Briefly, the aorta was ligated 
between the innominate and left common carotid arteries by tying a 7-0 silk suture 
around a tapered 27-gauge needle placed on top of the aorta.  The needle was 
removed, and a defined stenosis of the aorta was produced.  The skin was closed 
with separate sutures and buprenorphine was used as an analgesic.  
 
Angiotensin II Infusion 
Mice were anesthetized with 1.5% isoflurane and Ang II was infused for 28 
days at a rate of 3.2 mg·kg-1·day-1 by an osmotic minipump (Alzet) implanted 
subcutaneously.     
 
Histology 
 For heart-to-body weight ratios, mice were weighed and hearts were 
dissected, rinsed in PBS, and weighed.  Hearts were then cut transversely just 
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below the level of the papillary muscle.  The top half of the heart was fixed in 4% 
paraformaldehyde and 5μM sections were prepared.  The sections were stained with 
H&E to assess gross appearance, and Masson’s Trichrome staining was used to 
evaluate fibrosis.   
 
Echocardiography 
 Transthoracic echocardiography was performed with a 30-MHz probe and the 
Vevo 660 Ultrasonograph (VisualSonics).  Mice were anesthetized with 1-1.5% 
isoflurane.  Heart rate was closely monitored and mice were placed under a heat 
lamp to maintain a constant body temperature of 37°C.  The heart was imaged in a 
two-dimensional parasternal long-axis view.  For measurements, an M-mode cursor 
was positioned perpendicular to the interventricular septum and the posterior wall of 
the left ventricle at the level of the papillary muscle.   
 
Cardiomyocyte Contractility Measurements 
 Adult myocyte isolations were performed as previously described and 
subsequently used for contractility studies (38).  Cells of similar lengths were 
selected and single-cell contractions were measured in rod-shaped cells by video 
edge-detection (Crescent Electronics).  Percent cell shortening was recorded upon 
electric field stimulation under basal conditions and following treatment with 1μM 
isoproterenol.  Fifteen cells were analyzed three times for each animal. 
 
Statistics 
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 Statistical analyses were performed with a Student t test with unequal 
variance. 
 
Results 
Generation of Cardiomyocyte-Specific Calcrl Knockout Mice 
To study the cardiomyocyte-specific role of the Calcrl gene we generated 
mice with a “floxed” Calcrl allele.  As shown in Figure 3.1A, we bred CalcrlFlox/Flox 
mice to mice that were heterozygous for the Calcrl gene and positive for the 
αMHCCre recombinase transgene, which is specifically expressed in 
cardiomyocytes (1).  By breeding into a Calcrl+/- genetic background, we ensured 
robust excision of a single floxed allele and thereby reduced the incidence of mosaic 
cellular excision.  Figure 3.1B shows a typical genotyping PCR with the four 
genotypes obtained from the above-mentioned cross.  For the following 
experiments, we used Calcrl+/LoxP;αMHCCre+ mice as controls and Calcrl-
/LoxP;αMHCCre+ mice as cardiomyocyte-specific Calcrl knockouts.  By using mice 
that are αMHCCre+ for both controls and knockouts we excluded the possible toxicity 
of Cre as a basis for our phenotypes.  Figure 3.1C shows a PCR of genomic DNA 
samples isolated from hearts and tails.  Only DNA isolated from αMHCCre+ heart 
samples, in which exons 5 and 6 were excised by Cre-mediated recombination, 
yielded the 500 bp recombined allele.   
As shown in Figure 3.1D, all four genotypes generated from our crosses 
were observed in the expected Mendelian ratios, including the cardiomyocyte-
specific Calcrl knockouts.  All of these mice survived well into adulthood with no 
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obvious phenotypic defects.  Therefore, we conclude that the expression of Calcrl in 
cardiomyocytes is not required for normal embryonic development and survival.  
We also generated cardiomyocyte-specific Calcrl knockouts by crossing our 
mice to the cardiac troponin Cre (cTNTCre) line and observed similar results (data 
not shown).  Therefore, we conducted the rest of our studies using only the 
αMHCCre line.   
 
Cardiac Function in Cardiomyocyte-Specific Calcrl Knockouts  
To assess functional and morphological parameters under basal conditions, 
anesthetized 12-15 week old male mice were subjected to echocardiography.  Table 
3.1 shows that none of the physiological parameters we measured were significantly 
different between Calcrl+/LoxP and Calcrl-/LoxP mice.  All of the measured parameters 
fell within the range of previously reported values (3, 24, 38).  
 
Response of Cardiomyocyte-Specific Calcrl Knockouts to TAC 
Although cardiac function in cardiomyocyte-specific Calcrl knockouts was 
normal under basal conditions, we were interested in their response to TAC for two 
main reasons.  First, AM+/- mice have previously been reported to suffer from greater 
cardiac hypertrophy and fibrosis following TAC than wild-type controls (35).  Second, 
genes involved in AM signaling, including Calcrl, are significantly elevated following 
TAC-induced pressure overload (37).   
 Table 3.2 shows heart/body weight ratios and echocardiography data from 
sham-operated mice and mice that were subjected to TAC for 4 weeks.  Although 
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TAC treatment led to significantly elevated heart/body weight ratios in both 
genotypes, there were no significant functional differences between Calcrl+/LoxP and 
Calcrl-/LoxP mice in response to TAC.  The only statistically significant difference 
observed by echocardiography was the increase in LVPW, d and LV mass in Calcrl-
/LoxP mice following TAC.  Histological analysis of sham-operated animals shows that 
overall heart size, structure and interstitial fibrosis (Masson’s Trichrome) were similar 
in Calcrl+/LoxP and Calcrl-/LoxP mice (Figure 3.2A-3.2D).  Furthermore, histology 
shows that TAC resulted in enlarged left ventricular size and increased interstitial 
fibrosis, with no significant differences between the two genotypes (Figure 3.2E-
Figure 3.2H). 
 We also monitored the survival rate over the 4 week course of TAC 
challenge.  As shown by the Kaplan-Meier survival curve in Figure 3.3, 
approximately 30% of the animals died following TAC.  There were no significant 
differences in mean survival times or percent survival between Calcrl+/LoxP and Calcrl-
/LoxP mice.  All animals that underwent sham surgeries survived (data not shown).   
 Therefore, from these studies we conclude that loss of expression of Calcrl in 
cardiomyocytes does not substantially impact on the homeostatic response to 
pressure-induced cardiac hypertrophy. 
 
Response of Cardiomyocyte-Specific Calcrl Knockouts to Angiotensin II 
Niu et al. showed that cardiac hypertrophy induced by Ang II was more 
severe in AM+/- mice than wild-type controls (34, 35).  We therefore hypothesized 
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that cardiomyocyte-specific Calcrl knockouts might show a similar, more extreme, 
response when challenged with Ang II.   
Table 3.3 shows heart/body weight ratios and cardiac function in Calcrl+/LoxP 
and Calcrl-/LoxP animals after four weeks of Ang II treatment administered by osmotic 
minipumps.  While Ang II caused marked cardiac hypertrophy compared to sham 
and untreated animals (data not shown), there were no significant differences 
observed in any of the functional parameters measured.  Furthermore, histological 
analysis revealed no obvious differences in heart size, structure or fibrosis between 
the two genotypes after four weeks of Ang II challenge (Figure 3.4).  No animals 
died in the Ang II experiments (data not shown). 
We thus conclude that loss of Calcrl expression in cardiomyocytes does not 
significantly affect the heart’s response to Ang II-induced cardiac hypertrophy. 
 
Assessment of Cardiomyocyte Contractility 
To test the role of Calcrl in regulating contractility in a genetic model, we used 
single cell suspensions of cardiomyocytes from Calcrl+/LoxP and Calcrl-/LoxP  animals 
and measured percent cell shortening under basal and isoproterenol (1μM) 
stimulated conditions.  We found no significant differences between Calcrl+/LoxP and 
Calcrl-/LoxP  cardiomyocytes in percent cell shortening under basal conditions.  As 
expected, isoproterenol treatment significantly increased percent cell shortening in 
myocytes of both genotypes, but no significant differences were observed between 
the two groups (Figure 3.5). 
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Therefore, we conclude that loss of Calcrl expression does not substantially 
affect basal or isoproterenol-stimulated cardiomyocyte contractility. 
                  
Discussion 
AM is a multifunctional peptide that is secreted by several cell types including 
endothelial cells, vascular smooth muscle cells and cardiomyocytes (11).  Of 
particular interest in the AM field is its role in cardiovascular physiology and disease.  
Multiple studies in both animals and humans have strongly supported a protective 
role for AM in heart disease (7, 16, 27, 28, 34, 35).  However, our understanding of 
AM physiology is still incomplete due to several factors, including embryonic lethality 
of AM and Calcrl knockouts and a broad expression pattern of AM and genes 
involved in its signaling.  To better understand the role of AM signaling in cardiac 
development and physiology, we generated mice with a “floxed” Calcrl allele and 
crossed them to αMHC Cre mice, resulting in deletion of the Calcrl gene specifically 
in cardiomyocytes.  We chose to delete Calcrl, rather than AM, because AM is 
secreted by various cell types and acts in a paracrine manner, so that its genetic 
excision in one cell type may not preclude its activity within that cell.  By generating 
mice with a conditional deletion of the AM receptor, Calcrl, the loss of AM signaling 
in a specific cell type can be readily addressed. 
 Since the original Calcrl+/- mice have no obvious phenotypic defects (9), we 
were able to incorporate them into our breeding strategy for generating 
cardiomyocyte-specific Calcrl knockouts.  Calcrl+/Flox and Calcrl-/Flox mice only 
required one floxed allele to be deleted by Cre-mediated recombination, therefore 
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limiting the possibility of mosaic cellular excision.  Successful Cre-mediated 
cardiomyocyte-specific deletion of Calcrl was confirmed by detection of the null allele 
exclusively in the myocardium of αMHCCre+ Calcrl-floxed mice.  Four genotypes 
were obtained from our breeding strategy and all of them were observed at the 
expected Mendelian ratios well into adultdhood.  Thus, we conclude that the specific 
loss of Calcrl in cardiomyocytes is not the cause of generalized edema or embryonic 
lethality previously observed in global Calcrl knockout mice.  Consistent with this 
conclusion is the observation that loss of Calcrl in endothelial cells leads to an 
embryonic lethal phenotype similar to that observed in the global knockouts (JCI in 
press). 
 The viability of Calcrl-/LoxP mice allowed us to address the role of AM signaling 
in cardiomyocytes of normal and challenged adult animals.  We performed 
echocardiography in cardiomyocyte-specific Calcrl knockouts under basal conditions 
to evaluate cardiac structure and function.  Structural and functional characteristics 
of cardiomyocyte-specific knockouts were strikingly similar to controls, with no 
significant differences between any of the measured parameters.    
  Although basal cardiac function was normal in cardiomyocyte-specific Calcrl 
knockouts, we hypothesized that their response to cardiac challenge might be 
altered.  Several lines of evidence led us to propose this theory.  First, AM peptide 
levels are significantly elevated in human heart disease and in various animal 
models of cardiac challenge (17, 18, 22, 30-32).  Second, AM has consistently been 
shown to be cardioprotective in a number of disease conditions, especially heart 
disease.  AM serves several protective mechanisms, including inhibition of fibrosis 
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and collagen production by fibroblasts (16, 35), increasing coronary blood flow (27), 
reducing blood pressure (15, 23, 29), enhancing cardiomyocyte contractility (13) and 
reducing plasma aldosterone levels (6).  Finally, genes involved in AM signaling, 
including Calcrl, are dynamically regulated in the myocardium during cardiovascular 
stress (8, 32, 45).  Therefore, it was somewhat surprising that the cardiomyocyte-
specific Calcrl knockouts and controls responded similarly to cardiac challenge 
induced by aortic constriction or Ang II infusion.  As our results show, there were no 
significant differences between knockouts and controls in cardiac structure, function 
or survival in either of the models tested.  From these data we conclude that 
signaling for AM in cardiomyocytes does not represent the major protective function 
of this peptide to cardiovascular damage.   
 The role of AM signaling in regulating cardiomyocyte contractility is somewhat 
controversial.  Although this topic has been investigated in great detail by others (13, 
14, 26, 42), this study is the first to use a genetic model.  By measuring percent cell 
shortening in individually isolated myocytes, we concluded that there were no 
significant differences in contractility between control and knockout cells.   
 The results of our study are surprising.  The AM peptide seemingly plays a 
major role in cardiovascular biology, but knocking out its primary receptor in 
cardiomyocytes has no effect?  There are a few possible explanations for this 
observation.  One is that AM signaling through Calcrl is more important in other cell 
types, such as endothelial cells or vascular smooth muscle cells.  Indeed, we have 
recently reported that mice lacking Calcrl specifically in endothelial cells suffer from 
vascular defects and generalized edema which ultimately leads to death at mid-
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gestation, similar to global AM and Calcrl knockouts (JCI in press).  Therefore, it is 
possible that the cardioprotective effects observed in humans or animals treated with 
AM occur in response to a primary effect of AM on the vasculature.  Furthermore, 
most genetic animal models reported to date disrupt AM expression in all tissues.  
Since the disease models we have used in this study are complex and involve 
multiple cardiovascular components, this may be a reason we did not observe 
significant differences in cardiomyocyte-specific knockouts.  Another possible 
explanation which we cannot rule out is the possibility of another AM receptor in 
cardiomyocytes which may compensate for the loss of Calcrl.  Other putative AM 
receptors have been suggested to mediate the biological actions of AM (2, 20, 21).   
 This study was the first to examine the cardiomyocyte-specific role of the AM 
receptor, CLR.  We show that Calcrl expression in cardiomyocytes is not required for 
embryonic survival or for the cardioprotective functions of AM in response to 
pressure overload or Ang II-induced cardiovascular disease of adult animals.    
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Figure 3.1 
 
 
 
 
  
 
  
 
 
 
 
 
 
 
Figure 3.1: Generation of cardiomyocyte-specific Calcrl knockout mice.  (A) 
Schematic representation of the breeding scheme used to generate mice with Calcrl 
expression deleted specifically in cardiomyocytes by use of the αMHCCre 
transgene.  (B) Typical genotyping PCR showing the four possible genotypes which 
can result from the crosses depicted in 1A.  (C) PCR from tail or heart genomic DNA 
shows that the recombined allele which results from Cre-mediated recombination is 
only detected in Cre+ cardiac tissue.  (D) Results from cross demonstrate that all 
four possible genotypes are observed at the expected Mendelian ratios.  
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Figure 3.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Histological examination of the heart.  (A&C) H&E stained hearts 
from sham operated animals.  (B&D) Masson’s trichrome stained hearts of sham 
operated animals.  (E&G) H&E stained hearts from TAC animals.  (F&G) Masson’s 
trichrome stained hearts from TAC animals. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 84
Figure 3.3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: Survival rate after aortic constriction.  Percent survival after 28 days 
of aortic constriction.  No significant differences were observed between the two 
groups.   
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Figure 3.4 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: Histological examination of Ang II treated hearts. (A&C) H&E stained 
hearts from Ang II treated animals.  (B&D) Masson’s trichrome stained hearts from 
Ang II treated animals.   
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Figure 3.5 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5: Cardiomyocyte contractility.  Basal and 1 μM isoproterenol-induced 
percent cell shortening of Calcrl+/LoxP and Calcrl-/LoxP cardiomyocytes.     
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Table 3.1 
 
  
Ta  ble 1
Basal physiological parameters in control and Calcrl myocyte-specific knockouts 
 
 Calcrl +/LoxP;MHC Cre+ Calcrl -/LoxP;MHC Cre+ p value 
N 11 11  
Heart Rate (bpm) 446 ± 17 446 ± 16 1.00 
LVED, d (mm) 4.04 ± 0.13 3.95 ± 0.11 0.56 
LVED, s (mm)  3.03 ± 0.16 2.91 ± 0.15 0.55 
LVPW, d (mm) 0.74 ± 0.05  0.79 ± 0.07 0.35 
LVPW, s (mm) 1.03 ± 0.04 1.11 ± 0.05 0.23 
% FS 25 ±  2 26 ± 2 0.69 
%EF 49 ± 3 51 ± 4 0.71 
CO (ml/min) 16 ± 1 15 ± 1 0.89 
LV Mass (mg) 121 ± 9 117 ± 6 0.73 
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Table 3.2 
  
Table 2 
Physiological parameters in control and Calcrl myocyte-specific knockouts after 
four weeks of transverse aortic constriction (TAC) 
 
                                                       Calcrl +/LoxP;MHC Cre+            Calcrl -/LoxP;MHC Cre+  
                                                  
 Sham TAC Sham TAC 
N 4 6 4 6 
Heart/Body Weight 4.41 ± 0.26 7.89 ± 0.89* 4.33 ± 0.24 7.06 ± 0.80* 
Heart Rate (bpm) 494 ± 46 462 ± 23 449 ± 33 463 ± 17 
LVED, d (mm) 3.93 ± 0.17 4.04 ± 0.24 3.89 ± 0.19 3.98 ± 0.17 
LVED, s (mm) 3.08 ± 0.14 3.28 ± 0.35 2.95 ± 0.29  3.22 ± 0.20 
LVPW, d (mm) 0.91 ± 0.17 1.12 ± 0.11 0.82 ± 0.06 1.13 ± 0.08* 
LVPW, s (mm) 1.23 ± 0.21 1.38 ± 0.12 1.22 ± 0.10 1.35 ± 0.08 
%FS 21 ± 3 19 ± 4 24 ± 4 18 ± 2 
%EF 43 ± 6 39 ± 8 47 ± 8 39 ± 4 
CO (ml/min) 15 ± 3  12 ± 2 14 ± 2 12 ± 1 
LV Mass (mg) 154 ± 17 170 ± 24 119 ± 3 193 ± 22* 
 
*P<0.05 in sham vs. TAC within the same genotype. 
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Table 3.3 
 
  
Table 3 
Physiological parameters in control and Calcrl myocyte-specific knockouts 
following four weeks of angiotensin II treatment. 
 
 Calcrl +/LoxP;MHC Cre+ Calcrl -/LoxP;MHC Cre+ p value
N 4 4 
Heart/Body Weight 6.71 ± 0.15 6.56 ± 0.69 0.82 
Heart Rate (bpm) 451 ± 35 529 ± 37 0.08 
LVED, d (mm) 3.39 ± 0.14 3.65 ± 0.43 0.55 
LVED, s (mm)  2.48 ± 0.17 2.58 ± 0.45 0.82 
LVPW, d (mm) 1.23 ± 0.04 1.20 ± 0.06 0.66 
LVPW, s (mm) 1.54 ± 0.11 1.48 ± 0.06 0.58 
% FS 27 ±  3 29 ± 4 0.69 
%EF 53 ± 4 57 ± 6 0.62 
CO (ml/min) 11 ± 1 17 ± 3 0.16 
LV Mass (mg) 143 ± 14 148 ± 23 0.86 
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CHAPTER 4 
 
receptor activity modifying proteins 2 AND 3 HAVE DISTINCT 
PHYSIOLOGICAL FUNCTIONS FROM EMBRYOGENESIS TO OLD AGE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abstract 
Receptor activity modifying proteins (RAMPs) impart remarkable effects on G-
protein coupled receptor (GPCR) signaling.  First identified through an interaction 
with the calcitonin receptor-like receptor (CLR), these single transmembrane 
proteins are now known to modulate the in vitro ligand binding affinity, trafficking and 
second messenger pathways of numerous GPCRs.  Consequently, the receptor-
RAMP interface represents an attractive pharmacological target for the treatment of 
disease.  Although the three known mammalian RAMPs differ in their sequences 
and tissue expression, results from in vitro biochemical and pharmacological studies 
suggest that they have overlapping effects on the GPCRs with which they interact.  
Therefore, to determine whether RAMP2 and RAMP3 have distinct functions in vivo 
we generated mice with targeted deletions of either the Ramp2 or Ramp3 gene.  
Strikingly, we find that while Ramp2 is required for survival, mice that lack Ramp3 
appear normal until old age, at which point they have decreased weight.  In addition, 
mice with reduced expression of Ramp2, but not Ramp3, display remarkable sub-
fertility.  Thus, each gene has functions in vivo that cannot be accomplished by the 
other.  Because RAMP2, RAMP3 and CLR transduce the signaling of two potent 
vasodilators, adrenomedullin and calcitonin gene related peptide, we tested the 
effects of our genetic modifications on blood pressure and no effects were detected.  
Nevertheless, our studies reveal that RAMP2 and RAMP3 have distinct physiological 
functions throughout embryogenesis, adulthood and old age, and the mice we have 
generated provide novel genetic tools to further explore the utility of the receptor-
RAMP interface as a pharmacological target.         
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Introduction 
The identification of receptor activity modifying proteins 1-3 (RAMPs) has 
revolutionized our current understanding of the mechanism through which class II G-
protein coupled receptors (GPCRs) bind to their peptide ligands.  First identified in 
association with the calcitonin receptor-like receptor (CLR, formerly called CRLR), 
either of these three single-pass transmembrane proteins can bind to a GPCR, 
chaperone it to the plasma membrane and alter the ligand binding affinity of the 
receptor (23).  For example, a CLR/RAMP1 complex preferentially and specifically 
binds to calcitonin gene related peptide (CGRP) while a CLR/RAMP2 or 
CLR/RAMP3 complex will preferentially bind to adrenomedullin (AM), another 
peptide vasodilator.  Thus, the different spatial and temporal expression patterns of 
RAMP1, RAMP2 and RAMP3 determine how a cell or tissue will sense and respond 
to either extracellular CGRP or AM. 
Biochemical studies using heterologous over-expression of RAMPs in 
cultured cells have demonstrated that this general mechanism also applies to 
several other GPCRs of the class II family, including calcitonin (CT) receptor, 
parathyroid receptors 1 and 2, vasointestinal peptide/pituitary adenylate cyclase 
activating peptide 1 (VIP/VPAC1) receptor, and glucagon receptor (4, 5).  More 
recently, Bouschet et al. also demonstrated that RAMP1 or RAMP3 can functionally 
target a class III receptor, the calcium sensing receptor, to the plasma membrane 
(3).  Therefore it is likely that RAMP proteins have evolved to impart a highly 
controllable mechanism for modulating GPCR signaling that may be broadly 
applicable to many GPCRs (9).  As a consequence, the pharmacological and 
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biochemical study of the RAMP-receptor interaction has been geared towards 
identifying compounds that exploit this interface as a potential drug target for the 
specific modulation of GPCR signaling for the treatment of human disease (15).  
One such compound, BIBN4096BS which is currently in clinical trials for the 
treatment of migraine, acts as a selective CGRP antagonist by interfering with the 
hCLR/hRAMP1 interaction (7, 8).  Yet, the developmental and physiological 
consequences of genetically altering RAMP function or expression in the whole 
animal have not been addressed experimentally. 
Receptor-associated RAMPs have been linked with receptor glycosylation, 
receptor trafficking, ligand binding and alteration of second messenger signaling 
(recently reviewed (10, 13)).  However, these ascribed cellular functions are not 
consistently conserved among the different receptor-RAMP complexes and are 
highly affected by the choice of cell type and species of RAMPs studied (13).  
Moreover, pharmacological studies with the most well-characterized receptor-RAMP 
pairs, CLR/RAMP1-3 and CT/RAMP1-3, demonstrate varying degrees of overlap in 
the absolute ligand binding affinity imparted by the different RAMPs.  For example, 
CLR/RAMP1-3 complexes can all bind AM or CGRP, but with different affinities (12, 
18, 27), and CT/RAMP1-3 complexes can form amylin receptors with highly variable 
affinities (5, 26) or CGRP receptors (11, 19) depending on the cell type studied.  
Thus, it remains unclear to what degree the three mammalian RAMPs have 
overlapping functions or whether they can functionally compensate for each other in 
vivo. 
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To address these questions, we used gene targeting to generate mice with 
targeted deletions of either the Ramp2 or Ramp3 genes, and have determined the 
effects of their complete absence (in homozygous null mice) and of their reduced 
expression (in heterozygous mice). 
 
Experimental Procedures 
Generation of mice with targeted deletion of the Ramp2 or Ramp3 gene 
To generate the targeting vectors, a 129S6/SvEv genomic library was 
screened for phage clones containing the 5’ portions of the Ramp2 and Ramp3 
genes using DNA fragments isolated from hRamp2 or hRamp3 expression plasmids 
(kindly provided by Dr. Steven Foord, GlaxoSmithKline, UK).  Using convenient 
restriction sites within the genomic clones, 5’ and 3’ regions of homology were 
subcloned into the multiple cloning site of a gene targeting vector (osdupdel) which 
contained a PGK-neomycin cassette and an a HSV-thymidine kinase cassette.  The 
final targeting vectors were linearized with Not I before electroporation into 
embryonic stem (ES) cells. 
Standard gene targeting methods were utilized to generate ES cells and mice 
with a targeted deletion of the Ramp2 gene or a targeted deletion of the Ramp3 
gene (16).  Briefly, 129S6/SvEv-TC-1 ES cells were electroporated with the 
linearized targeting vectors shown in Fig. 4.1a and 4.2a, respectively.  After applying 
positive (G418) and negative (ganciclovir) selection, positive ES cell clones were 
identified by Southern blot and/or PCR.  The frequency of homologous 
recombination in the surviving G418/gancyclovir resistant colonies was 5% for 
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Ramp2 and 1.5% for Ramp3.  Male chimeric mice that transmitted the targeted allele 
were bred to 129S6/SvEv females to establish isogenic lines. 
For PCR-based genotyping of the Ramp2 targeted locus we used three 
primers: primer 1: 5’- CTGAACTGAACAGCAGGGCCA-3’; primer 2: 5’ 
CGGCTACTTCCCACTTAATGCTG-3’; primer 3: 5’GCTTCCTCTTGCAAAACCACA-
3’.  Primers 1 and 3 amplify a 1.2 kb targeted band while primers 1 and 2 amplify a 
1.6 kb wildtype band. 
For PCR-based genotyping of the Ramp3 targeted locus we used four 
primers: primer 1: 5’-GCCCATGATGTTGGTCTCCA -3’; primer 2: 5’ 
GGTCATTAGGAGCCACGTGT-3’; primer 3: 5’GCTTCCTCTTGCAAAACCACA-3’; 
primer 4: 5’GGGCTAAAGAAGCCACAGCT-3’.  Primers 1 and 3 amplify a 2.0 kb 
targeted band while primers 2 and 4 amplify a 1.4 kb wildtype band. 
 
Gene Expression Analysis 
Ramp2, Ramp3 and Calcrl gene expression was analyzed by quantitative RT-
PCR with the Mx3000P Q-PCR machine from Stratagene. Primers for Ramp2 
amplification were 5’-CAGAATCAATCTCATCCCACTGAC-3’ and 5’-
GTCCATGCAACTCTTGTACTCATACC-3’.  The probe sequence for Ramp2 
detection was 5’-FAM-ATGGAAGACTACGAAACACATGTCCTACCTTG-TAMRA-3’.  
Primers for Ramp3 amplification were 5’-GGTCATTAGGAGCCACGTGT-3’ and 5’-
GGGCTAAACAAGCCACAGCT-3’.  The probe sequence for Ramp3 detection was 
5’-FAM-CACGATTCTGTGTCCAGTGTGGGCTG-TAMRA-3’.  Primer and probe 
sequences for detection of Calcrl gene expression were previously described (6).  -
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actin served as an internal control for all reactions. The primers used for -actin 
amplification were 5’-CTGCCTGACGGCCAAGTC-3’ and 5’-
CAAGAAGGAAGGCTGGAAAAGA-3’. The probe sequence for β-actin detection 
was 5’-TET-CACTATTGGCAACGAGCGGTTCCG-TAMRA-3’.  RNA was isolated 
from adult tissues or E13.5 embryos with TRIzol Reagent (GIBCO/BRL) and 
subsequently DNase treated and purified with an RNeasy Mini Kit (Qiagen). 200 ng 
of total RNA was used in each reaction. The ΔΔCt method (21) was used to 
determine the relative levels of gene expression and shown as a percentage of wild 
type. All assays were repeated three times, each with duplicates. 
 
Measurement of Basal Blood Pressure, Heart Rate and Urine Chemistry 
Blood pressures and heart rates were measured on unanesthetized mice by a 
computerized tail cuff system (17).  Urine and protein creatinine were measured at 
UNC-CH’s Animal Clinical Chemistry Core Facility.   
 
Experimental Animals 
Unless otherwise noted, experimental animals were 4-8 months old and 
maintained on an isogenic 129S6/SvEv-TC-1 background.  Control animals for all 
experiments consisted of wildtype, age- and gender-matched littermates.  All 
experiments were approved by the Institutional Animal Care and Use Committee of 
The University of North Carolina at Chapel Hill.  
 
Statistics 
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Statistical analyses for multiple comparisons were performed with Oneway 
ANOVA by JMP Software, SAS Institute.  Error bars represent standard error of the 
means.  Differences were considered significant with a p value of < 0.05.     
 
Results 
Generation of heterozygous mice with targeted disruption of the Ramp2 gene 
Mice in which exons 1 and 2 of the Ramp2 gene were deleted by homologous 
recombination were generated using the targeting strategy shown in Figure 4.1A. 
The disrupted allele, which lacks the Ramp2 promoter, 5’ untranslated region, 
translation start site and exons 1 and 2, was confirmed by genomic PCR (Fig. 4.1B).  
To confirm that the gene targeting effectively disrupted transcription of the Ramp2 
gene, quantitative reverse transcription-PCR for Ramp2 RNA was performed on total 
RNA isolated from whole embryos. As expected and shown in Figure 4.1C, Ramp2+/- 
embryos expressed approximately half of wildtype Ramp2 RNA levels (58%, p< 
0.001 vs. wildtype) while Ramp2-/- embryos had no detectable levels of Ramp2 RNA, 
thus confirming correct gene targeting of the Ramp2 gene (Figure 4.1C).  To 
determine whether genetic reduction of Ramp2 caused a homeostatic compensation 
in the expression of the Ramp3 or Calcrl genes, we measured the expression of 
these genes in the heart and kidneys of adult Ramp2+/- animals and in total RNA 
isolated from mid-gestation Ramp2-/- embryos.  As shown in Figure 4.1D, we found 
no significant compensatory increase in the expression of either Ramp3 or Calcrl in 
Ramp2+/- or Ramp2-/- mice compared to wildtype controls, demonstrating that the 
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genetic reduction of Ramp2 does not result in a compensatory up-regulation of 
Ramp3 or Calcrl gene expression.     
 
Generation of mice lacking the Ramp3 gene 
Homozygous null mice for the Ramp3 gene were generated by homologous 
recombination using the targeting strategy shown in Figure 4.2A. The disrupted 
allele, which lacks exons 2 and 3 of the Ramp3 gene (coding for amino acids 19-147 
of 147 total amino acids), was detected by Southern blot analysis using a genomic 
probe fragment located outside the areas of homology (Fig. 4.2B) and by genomic 
PCR (Fig. 4.2C). The correctly targeted allele was further confirmed by direct 
sequencing (data not shown).  To confirm that the gene targeting effectively 
disrupted transcription of full length Ramp3 mRNA, quantitative reverse 
transcription-PCR for Ramp3 mRNA was performed on total RNA isolated from adult 
kidneys.  As expected, Ramp3+/- mice expressed approximately half of wildtype 
Ramp3 RNA levels (45%, p< 0.0001 vs. wildtype) while Ramp3-/- mice had no 
detectable levels of Ramp3 RNA, thus confirming complete loss of Ramp3 
expression in adult homozygous mice (Fig. 4.2D).  To determine whether genetic 
deletion of Ramp3 caused a homeostatic compensation in the expression of the 
Ramp2 or Calcrl genes in adult animals, we measured the expression of these 
genes in the heart and kidneys of Ramp3-/- animals.  As shown in Figure 4.2E, we 
found no significant compensatory increase in the expression of either Ramp2 or 
Calcrl genes in Ramp3-/- mice compared to wildtype controls, demonstrating that the 
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genetic deletion of Ramp3 does not impact on the regulation of Ramp2 or of Calcrl 
gene expression. 
Ramp2 is essential for survival and normal fertility 
 In marked contrast, while the loss of Ramp3 did not affect the survival of 
Ramp3-/- mice to adulthood, we found that genetic loss of Ramp2 caused embryonic 
lethality since no Ramp2-/- pups were born alive to heterozygote matings.  This 
remarkable contrast in phenotypes (embryonic lethality of Ramp2-/- mice versus 
survival of Ramp3-/- mice) demonstrates that these two genes have significantly 
different functions during embryonic development.  
Offspring from Ramp3+/- matings were born in the expected Mendelian ratio of 
1:2:1 (26 Ramp3+/+:48 Ramp3+/-:25 Ramp3-/- pups from 15 litters) and had litter sizes 
comparable to isogenic control matings (6.6 pups/litter for Ramp3+/- matings versus 
6.0 pups/litter for 129S6/SvEv isogenic control matings, Figure 4.3).  In contrast, 
although the ratio of wildtype:heterozygote genotypes for viable pups born to 
Ramp2+/- matings was in the expected Mendelian distribution of 1:2 (22 Ramp2+/+:44 
Ramp2+/- pups from 29 litters), the average litter size was significantly reduced to 2.1 
pups per litter at wean.  This markedly reduced litter size is significantly below the 
expected litter size of 4.5 pups/litter, which takes into consideration the gestational 
loss of Ramp2-/- null embryos (further confirmed by the assessment of litter sizes for 
Calcrl heterozygote matings in which there is gestational loss of null embryos (6), 
Figure 4.3).  Thus, while genetic loss of Ramp3 was dispensable for normal fertility, 
a modest genetic reduction of Ramp2 was sufficient to cause marked sub-fertility, 
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demonstrating that the two genes maintain distinct physiological functions during 
adulthood.  
 
Aged Ramp3-/- mice fail to gain weight 
Ramp3-/- mice survived to adulthood, reproduced and displayed no obvious 
phenotypic defects until ~6 months of age.  Although the body weights of young 
Ramp3-/- mice did not differ from their wildtype controls up to ~6 months of age 
(Table 4.1), we noticed that older Ramp3-/- mice (9-10 months of age) weighed 
nearly 9 grams less than age-matched wildtype mice (Figure 4.4B, wildtype mice 
weighed 36.1 +/- 1.9 g versus 27.3 +/- 1.1 g for age-matched Ramp3-/- mice).  In 
contrast, aged Ramp2+/- mice did not differ significantly in body weights from their 
wildtype littermates (Figure 4.4A, wildtype weighed 28.3 +/- 0.5 g versus 28.8 +/- 0.7 
g for age-matched Ramp2+/- mice).   Despite their visibly lean appearance, we found 
no significant differences in food or water intake in either young or aged Ramp3-/- 
mice compared to their age-matched, wildtype controls (Table 4.1).  Moreover, 
Ramp3-/- mice, like their wildtype counterparts, survived to at least 18 months of age 
with no obvious decline in health.  Since Ramp3 is highly expressed in the proximal 
tubule of the kidney, we also compared urine volume and kidney function (as 
determined by protein/creatinine ratio) between Ramp3-/- mice and wildtype controls 
and found no obvious differences (Table 4.1).  The body weights, feeding behavior 
and kidney function of Ramp2+/- mice or Calcrl+/- mice did not differ from wildtype 
control littermates (Table 4.1). 
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Blood pressures and heart rates are unaffected in Ramp2+/- and Ramp3-/- mice  
Because CLR is the best characterized receptor partner for RAMP2 and 
RAMP3 and because CLR binds to two potent peptide vasodilators (AM and CGRP), 
we sought to compare the blood pressures and heart rates of Ramp2+/- and Ramp3-/- 
mice to those of Calcrl+/- (6) and wildtype mice using a computerized tail cuff system.  
As shown in Table 4.1, we found that reduction of Ramp2 to ~50% of wildtype levels 
and complete absence of Ramp3 had no effect on the basal blood pressures of 
conscious animals compared to wildtype mice or to Calcrl+/- mice.  Moreover, we 
found no overt differences in the heart rates among the genotypes tested (Table 
4.1). 
   
Discussion 
In summary, we used gene targeting to generate two independent mouse 
lines with deletion of either the Ramp2 or Ramp3 genes.  Gene expression analysis 
in mice with reduced or absent Ramp2 levels or complete lack of Ramp3 did not 
reveal any compensatory up-regulation of either Ramp3 or Ramp2 gene expression, 
respectively, supporting our conclusion that there is no functional redundancy at the 
transcriptional level between Ramp2 and Ramp3 in vivo.  We did observe a general 
trend for significantly reduced expression of Ramp2, Ramp3 and Calcrl compared to 
wildtype mice in the models we tested (Fig. 4.1D and Fig. 4.2E) which is likely 
reflective of the high sensitivity of these genes to altered physiological homeostasis 
(18, 27). 
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Although the biochemical and pharmacological profiles of RAMP2 and 
RAMP3 appear to overlap for certain GPCRs (CLR, CT and VIP/VPAC1), our 
genetic studies demonstrate that the two genes have distinct roles throughout the 
life of an animal.  During embryonic development, Ramp2-/- mice fail to survive while 
Ramp3-/- mice appear normal up to 6 months of age.  During adulthood, loss of 
Ramp3 had no apparent effect on fertility.  In contrast, a modest genetic reduction of 
Ramp2 in heterozygous mice was sufficient to cause a marked reduction in litter 
size, which is similar to the phenotype we have previously characterized for mice 
with a genetic reduction of AM (20).  Finally, in aged animals we found that Ramp3, 
but not Ramp2, plays an important role in maintaining normal body weight, however 
the physiological mechanisms which account for this phenotype have not yet been 
resolved. 
Our studies to address the regulation of  blood pressure and heart rate in 
these mice are consistent with our recent findings demonstrating that genetic 
alteration of AM peptide levels from 50%-140% wildtype levels does not affect basal 
blood pressure.  These results are also consistent with another recent study where 
transgenic over-expression of mRamp2 in smooth muscle cells had no effect on 
basal or induced changes in blood pressure (25).  Lu et al have also shown that 
genetic deletion of α-CGRP does not alter basal blood pressure in mice (22).  Taken 
together, our results indicate that in vivo genetic alteration of Ramp2, Ramp3 or 
Calcrl expression (the receptor signaling components required for transducing the 
signal of two potent vasodilators, AM and CGRP) does not impact on basal blood 
pressure regulation in mice.  Thus, the use of CLR/RAMP2 or CLR/RAMP3 as 
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pharmacological targets for the treatment of hypertension in humans should be 
carefully evaluated. 
Our most significant data stem from the direct comparison of phenotypes for 
the Ramp2 and Ramp3 gene targeted mice.  While modest changes in the genetic 
dosage of the Ramp2 gene have profound effects on survival and reproduction, 
complete absence of the Ramp3 gene seems to have little or no effect on mice until 
old age.  These in vivo findings are consistent with the concept that RAMP2 acts to 
mediate the basal effects of normal GPCR signaling while RAMP3 may become 
induced under physiological conditions (14) or disease (24) to alter the signaling of 
GPCRs (10).  This concept is further supported by biochemical studies which 
demonstrate that RAMP3, but not RAMP2, contains an intracellular PDZ motif 
capable of binding to NSF and NHERF to change receptor internalization and 
trafficking (1, 2).  Thus, the continued study of these genetically engineered mouse 
models under normal conditions and disease states, as well as cell lines derived 
from them, will provide useful tools for unraveling the functional role of RAMP2 and 
RAMP3 in modulating GPCR signaling and testing their potential utility as 
pharmacological targets for the treatment of human disease. 
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Figure 4.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.1. Gene targeting of Ramp2. A, schematic representation of the strategy 
used to disrupt the Ramp2 gene in mice. The promoter region and exons 1 and 2 of 
Ramp2, including the initiator methionine were deleted by homologous 
recombination. B, BamHI X, Xho, Xb, and Xba and P1, P2, and P3 primers used for 
screening and genotyping. B, genomic PCR for detection of the wild type and 
targeted alleles using total embryonic DNA extracts and the primers depicted in Fig. 
4.1A. C, quantitative RT-PCR for detection of Ramp2 mRNA transcripts using total 
embryonic RNA extracts and the primers and probes described under "Experimental 
Procedures." ND, not detected. D, quantitative RT-PCR for detection of Ramp2, 
Ramp3, and Calcrl mRNA transcripts using total RNA extracted from the hearts and 
lungs of Ramp2+/– adult mice and Ramp2–/– embryos. 
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Figure 4.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.2. Gene targeting of Ramp3. A, schematic representation of the strategy 
used to disrupt the Ramp3 gene in mice. Exons 2 and 3 of Ramp3, including the last 
129 amino acids (of 147 total), the stop codon, and the 3'-untranslated region were 
deleted by homologous recombination. Shown are AvrII (A), Kpn (K), PvuII (P), and 
SacI (S) and P1, P2, P3, and P4 primers used for screening and genotyping. B, 
Southern blot for detection of the wild type and targeted alleles using genomic DNA 
and the probe fragment depicted in Fig. 4.2A. C, genomic PCR for detection of the 
wild type and targeted alleles using total DNA extracts and the primers depicted in 
Fig. 4.2A. D, quantitative RT-PCR for detection of Ramp3 mRNA transcripts using 
total RNA extracted from adult kidneys and the primers and probes described under 
"Experimental Procedures." ND, not detected. E, quantitative RT-PCR for detection 
of Ramp2 and Calcrl mRNA transcripts using total RNA extracted from the hearts 
and lungs of Ramp3–/– adult mice. 
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Figure 4.3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.3. Severely reduced fertility in Ramp2+/– mice. Average litter sizes at 
weaning resulting from heterozygote matings of the genotype indicated. The number 
at the bottom of each bar represents the total number of litters. Litter size of Calcrl+/– 
matings is significantly reduced because of the previously reported embryonic 
lethality of Calcrl–/– embryos (18). *, p < 0.05 by analysis of variance. 
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Figure 4.4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.4. Reduced body weights in aged Ramp3–/– mice (but not aged Ramp2+/– 
mice). A, body weights of 9–10-month-old Ramp2+/– mice compared with their age-
matched isogenic controls (Student's t test, p = 0.6, n = 7 for each group). B, body 
weights of 9–10-month-old Ramp3–/– mice compared with their age-matched, 
isogenic controls (Student's t test, p < 0.001, n = 10 for each group). 
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Table 4.1 
 
Phenotypic analysis of Ramp2+/– and Ramp3–/– mice 
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CHAPTER 5 
MICE HETEROZYGOUS FOR ADRENOMEDULLIN EXHIBIT A MORE 
EXTREME INFLAMMATORY RESPONSE TO ENDOTOXIN-INDUCED 
SEPTIC SHOCK 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abstract 
Adrenomedullin (AM) is a highly conserved peptide that can act as a potent 
vasodilator, anti-microbial factor and anti-inflammatory factor.  Several studies have 
implicated diverse roles for AM in regulating the inflammatory and hemodynamic 
responses to septic shock.  Moreover, during sepsis the receptors that mediate AM 
signaling [calcitonin receptor-like receptor (Calcrl) and receptor activity modifying 
proteins (Ramp) 2 and 3] undergo dynamic and robust changes in their expression.  
Although numerous studies have used animal models to study the role of 
administered or increased AM in septic animals, genetic studies to determine the 
consequences of reduced AM during septic shock have not yet been performed.  
Here, we used a murine model of lipopolysaccharide (LPS)-induced septic shock to 
assess the inflammatory response in mice heterozygous for the AM gene.  Following 
LPS challenge, AM+/- mice had higher expression of TNF-α and IL-1β than LPS-
treated wild-type (WT) controls. Consequently, serum TNF-α was also significantly 
elevated in LPS-treated AM+/- mice compared to WT LPS-treated mice.  We also 
observed higher serum levels of liver enzymes, suggesting more advanced end-
organ damage in mice with genetically reduced AM.  Finally, we found that Ramp2 
and Calcrl expression levels were markedly reduced in LPS-treated mice, whereas 
Ramp3 expression was significantly elevated.  Importantly, these changes in 
receptor gene expression were conserved in AM+/- mice, demonstrating that AM 
peptide itself does not impact directly on the expression of the genes encoding its 
receptors.  We therefore conclude that during septic shock the dynamic modulation 
of AM and its receptors primarily functions to dampen the inflammatory response. 
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Introduction 
Adrenomedullin (AM) is a highly conserved gene that may have evolved from 
an antimicrobial peptide in early eukaryotic organisms into a potent vasodilator in 
higher mammalian species (34).  AM causes relaxation of vascular smooth muscle 
cells (VSMCs) (6), reduces endothelial cell permeability (9) and is a biologically-
relevant antimicrobial peptide involved in the innate immune response (1).  The 52-
amino acid peptide is produced and secreted by many mammalian tissues and is 
most highly expressed by VSMCs (27) and endothelial cells (26).  Stimuli for AM 
synthesis and secretion include angiotensin II, endothelin-1, hypoxia, oxidative 
stress and inflammatory cytokines such as TNF-α and IL-1β (5).  Thus, the biological 
functions of AM in mammals are numerous, diverse and likely inter-related.  
Plasma levels of AM are significantly elevated in humans with a wide variety 
of physiological conditions, including cardiovascular disease, normal pregnancy and 
septic shock (7).  In patients with septic shock, AM peptide levels are 25 to 30 fold 
higher than in normal individuals (10, 20).  Since AM is a potent vasodilator (14), it is 
reasonable to assume that increased plasma AM contributes to the extreme 
hypotension observed in the early stages of septic shock.  However, our recent 
studies using genetically engineered mice that lack one copy of the AM gene 
demonstrate that reduction of endogenous AM to 50% of wild-type (WT) levels has 
no effect on the acute hypotension that occurs in an LPS-induced murine model of 
septic shock (2).  These results suggest that AM may play other primary roles during 
septic shock.    
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AM possesses anti-inflammatory (8), bactericidal (1), and positive inotropic 
(11) properties, which are all beneficial responses to sepsis.  When treated with 
endotoxin, mice over-expressing AM in their vasculature experience less severe 
hemodynamic and inflammatory responses, less liver damage and lower mortality 
rates compared to WT endotoxin-treated controls (25).  AM has also been shown to 
reduce TNF-α expression and release in macrophage cell lines and rat Kupffer cells 
(30).  More recently, administration of AM to rats with α-toxin-induced sepsis 
reduced vascular hyperpermeability and resulted in dramatically improved survival 
rates (28).  Taken together, these results suggest that the beneficial roles of AM 
during septic shock may primarily be to minimize organ damage by influencing the 
immune response and/or vascular permeability, rather than by regulating blood 
pressure.  Yet, experiments to genetically confirm the primary function of AM during 
septic shock have not yet been performed. 
The AM peptide contains a 6-residue ring structure and amidated C-terminus 
which, due to conserved sequence homology and structural motifs, places it in the 
calcitonin family of peptides, including calcitonin, calcitonin gene related peptide 
(CGRP), amylin and intermedin (34).  Peptides of this family also share a unique 
mechanism of G-protein coupled receptor signaling by a novel class of single 
transmembrane proteins called receptor activity modifying proteins (RAMPs).  
RAMPs were first identified through their association with the calcitonin receptor-like 
receptor (CLR) and can interact with many other class II GPCRs to determine 
receptor ligand binding specificity (24).  In the case of CLR, association with RAMP1 
produces a CGRP receptor, while association with RAMP2 or RAMP3 produces a 
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receptor specific for AM.  In this way, the spatial and temporal expression of RAMP 
proteins determines the tissue responsiveness to either CGRP or AM.   
During inflammation and septic shock, there are robust and dynamic changes 
in the expression of the Ramp and Calcrl genes that are responsible for mediating 
AM signaling.  For example, TNF-α significantly reduced the expression of Calcrl 
(the gene encoding CLR), Ramp1 and Ramp2 in cultured human coronary artery 
smooth muscle cells in a time and dose-dependent manner (19).  Moreover, Ono et 
al. have also shown that Calcrl and Ramp2 expression was significantly decreased 
in lungs of LPS-induced septic mice, while Ramp3 expression levels were elevated 
nearly 40-fold (21).  In a related fashion, the amount of AM binding protein (AMBP) 
is significantly reduced during the hypodynamic phase of sepsis, which may account 
for the reduced responsiveness to elevated plasma AM during the late phase of 
sepsis (29, 31, 33, 34).  These results suggest that the modulation of AM signaling 
during septic shock is complex (involving both receptor modulation and active 
peptide bioavailability) and finely tuned in order to maintain homeostatic balance in 
response to severe physiological insults.  However, whether AM signaling itself is 
involved in these dynamic receptor responses remains unclear.   
Our previous studies with genetically engineered mouse models have shown 
that mice lacking both copies of the AM gene or the Calcrl gene die at mid-gestation 
from extreme hydrops fetalis and cardiovascular defects (3, 4).  Adult female mice 
heterozygous for AM display profound reproductive defects (15) and are protected 
from hypertension-induced cardiovascular end organ damage (2).  Otherwise, adult 
male and female AM heterozygous mice are born at the expected Mendelian ratios, 
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survive to adulthood and have normal blood pressures under basal and stressed 
conditions with no obvious phenotypic defects.   
To determine if genetic reduction of endogenous AM affects the septic 
response in mice, we challenged AM+/- mice in an LPS-induced model of septic 
shock.  Since AM is consistently reported as an anti-inflammatory peptide, we were 
particularly interested in determining whether genetic reduction of endogenous AM 
in vivo could alter the inflammatory response in septic animals.  We also used our 
genetic model to determine if the dynamic gene expression changes observed in the 
AM receptor signaling genes during septic shock are dependent on the expression 
levels of AM peptide.   
 
Experimental Methods 
Experimental Animals and LPS Treatment 
The generation and phenotype of mice with a targeted deletion of the AM 
gene have been previously described (3).  Experiments were carried out with 8-10 
week old male mice bred under a controlled environment and were approved by the 
Institutional Animal Care and Use Committee of the University of North Carolina, 
Chapel Hill.  Animals used in these experiments were produced by AM+/- 
intercrosses and were maintained on an isogenic 129S6/SvEv genetic background.  
To induce septic shock in WT and AM+/- mice, 60 mg/kg LPS (Escherichia coli 
O55:B5; Sigma, St. Louis, MO) was injected I.P. (unless otherwise stated).  
 
Gene expression analysis 
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Gene expression was analyzed by quantitative reverse transcription-PCR with 
the Mx3000P Real-Time PCR machine from Stratagene.  Taqman primer and probe 
sequences for Calcrl detection have recently been published.  Primers for Ramp2 
were 5’-CAGAATCAATCTCATCCCACTGA-3’ and 5’-
GTCCATGCAACTCTTGTACTCATAC-3’.  The probe for Ramp2 detection was 5’-
FAM-TGGAAGACTACGAAACACATGTCCTACCTTG-TAMRA-3’.  Primers for 
Ramp3 were 5’-GGTCATTAGGAGCCACGTGT-3’ and 5’-
GGGCTAAACAAGCCACAGCT-3’.  The probe for Ramp3 detection was FAM-5’-
CAGCCCACACTGGACACAGAATCGTG-TAMRA-3’.  For L1 detection, we used a 
pre-designed, Assays on Demand primer/probe set (Applied Biosystems).  Primers 
for TNF-α were 5’-CTGTCTACTGAACTTCGGGGTGAT-3’ and 5’-
GGTCTGGGCCATAGAACTGATG-3’.  The probe for TNF-α detection was 5’-FAM-
ATGAGAAGTTCCCAAATGGCCTCCCTC-TAMRA-3’.  Primer and probe sequences 
for IL-1β detection have been previously published (13).  A GAPDH primer/probe set 
was purchased from Applied Biosystems (part # 4308313) and used as an internal 
control for all samples.  RNA was isolated from lungs with Trizol reagent (Invitrogen), 
DNase treated, and purified with an RNeasy Mini Kit (Qiagen).  200 ng of RNA was 
used per reaction and each sample was run in triplicate.  The ΔΔCt method was 
used to determine the relative levels of gene expression (16).  
 
Measurement of serum TNF-α levels 
For basal in vivo serum TNF-α concentrations, tail-vein bleeds were 
performed prior to LPS challenge.  Mice were then administered LPS for one hour 
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and serum samples were again obtained by tail-vein bleed.  TNF-α concentrations 
were quantified using anti-TNF-α antibody by ELISA technique (product # 
EMTNFA2; Pierce, Rockford, IL).  Recombinant TNF-α was used as a standard 
control.  
 
ALT and AST measurement 
Blood chemical analysis for serum alanine (ALT) and aspartate (AST) 
aminotransferase activities was performed in the Animal Clinical Laboratory Core 
Facility of the University of North Carolina at Chapel Hill using a Chemical Analyzer 
VT250 (Ortho-Clinical Diagnostics Comp. Rochester, NY). 
 
Statistical analysis 
Statistical analysis was performed using a Student’s t test with unequal 
variance. A p value equal to or less than 0.05 was considered statistically significant. 
 
Results 
Elevated TNF-α and IL-1β expression in AM+/- septic mice 
Using quantitative RT-PCR, the expression of the pro-inflammatory cytokines 
TNF-α, IL-1β, and IL-6 was measured in WT and AM+/- mice treated with or without 
LPS for 45 minutes.  Both WT and AM+/- animals showed a robust and rapid 
increase in TNF-α expression following LPS administration.  However, induction of 
TNF-α expression was significantly higher in lungs of AM+/- mice than in lungs of WT 
control mice (Fig. 5.1).  Similarly, IL-1β expression was drastically elevated in both 
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WT and AM+/- mice upon LPS challenge, and this increase was significantly higher in 
AM+/- mice than in WT mice (Fig. 5.1).  Although the expression of IL-6 was higher in 
AM+/- mice than in WT controls, this data did not reach statistical significance (data 
not shown).  These results demonstrate that the lungs of mice with only one copy of 
the AM gene (AM+/-) are more susceptible to the inflammatory response of 
endotoxemic shock than WT mice with both copies of the endogenous AM gene.  
 
Elevated serum TNF-α levels in AM+/- septic mice 
Serum TNF-α was quantified using ELISA before and during LPS challenge in 
WT and AM+/- mice.  Basal TNF-α levels prior to LPS treatment were similar in both 
genotypes (30 pg/ml +/- 5.59 for AM+/- versus 19.41 pg/ml +/- 4.69 for WT, p=0.174, 
Fig.5.2).  Both WT and AM+/- mice had a marked elevation in TNF-α 1 hour after LPS 
administration.  However, AM+/- mice showed a more robust response and secreted 
more than two-fold higher TNF-α than WT mice within the first hour of LPS challenge 
(598.83 pg/ml +/- 59 for AM+/- versus 268.18 pg/ml +/- 41 for WT, p=0.0004, Fig.5.2).  
These results are consistent with our experiments measuring TNF-α gene 
expression and provide further evidence that AM+/- mice are more susceptible to 
LPS-induced inflammation than WT controls.  
 
Increased ALT and AST activity in AM+/- septic mice 
Liver damage is a hallmark characteristic of endotoxin-induced septic shock 
and can be assessed by liver enzyme activity.  Alanine aminotransferase (ALT) and 
aspartate aminotransferase (AST) are thus accurate indicators of liver cell damage 
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and inflammation (23).  In untreated mice of both genotypes, serum ALT levels were 
similar (11 U/L +/- 2.3 for AM+/- versus 9.73 U/L +/- 1.06 for WT, p=0.63).  Following 
a 24-hour, 100 mg/kg LPS challenge, AM+/- mice showed significantly higher ALT 
activity than WT controls (528.1 U/L +/- 158 for AM+/- versus 69.4 U/L +/- 15.6 for 
WT, p=0.02).  Similarly, basal serum AST activity was not significantly different 
between WT and AM+/- mice (105.7 U/L +/- 7.5 for AM+/- versus 111.8 U/L +/- 6.1 for 
WT, p=0.56).  However, after 24 hours of LPS challenge, AM+/- mice exhibited 
significantly higher AST activity (878 U/L +/- 181 for AM+/- versus 283.1 U/L +/- 45.5 
for WT, p=0.01) (Fig. 5.3).  Perhaps due to the isogenic 129S6/SvEv strain used in 
these studies, histological analysis and myeloperoxidase assays for neutrophil 
infiltration revealed no significant differences between LPS-challenged livers of WT 
and AM+/- mice.  Nevertheless, these data clearly demonstrate that reduction of AM 
gene expression by 50% in AM+/- mice leads to more severe end-organ damage 
after septic shock than in mice with 2 copies of the AM gene.  
 
Dynamic regulation of AM receptor genes in AM+/- septic mice 
To determine whether the expression of the AM gene affects homeostatic 
alterations in the expression of genes encoding for AM receptors (Calcrl, Ramp2, 
and Ramp3) during sepsis we used quantitative RT-PCR of total lung RNA from 
septic WT and AM+/- mice.  We found that Ramp2 and Calcrl expression levels were 
markedly reduced 97.3% and 98.1%, respectively, while Ramp3 expression was 
elevated 23.8 fold in WT mice treated with LPS.  Importantly, similar changes in 
gene expression were observed in AM+/- mice; Ramp2 expression was reduced 
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92.8%, Calcrl was reduced 95% and Ramp3 was elevated 24.9 fold (Fig. 5.4).  In 
addition, we also measured expression levels of another putative AM receptor, 
called L1, in WT and AM+/- septic mice, and found the expression level of this gene 
to be reduced in LPS-treated mice of both genotypes (75.7% reduction in WT mice 
and 68% reduction in AM+/- mice, data not shown).  Taken together, our results 
support the concept that robust and dynamic changes in the expression of genes 
responsible for mediating AM signaling occur during septic shock. Moreover, since 
the magnitude of these changes was not different between WT and AM+/- mice, we 
conclude that the level of AM peptide is not primarily involved in mediating 
responsiveness to AM signaling at the level of receptor expression.  
 
Discussion 
Many in vitro studies have suggested an important regulatory role for AM in 
sepsis and other inflammatory diseases (12, 17, 18, 27, 30, 32).  Moreover, genetic 
over-expression of AM in the mouse vasculature or therapeutic administration of AM 
peptide in rats or mice had beneficial effects on reducing the inflammatory and 
hemodynamic insults elicited in septic shock (25).  However, whether genetic 
reduction of AM can cause a more severe response to sepsis has not yet been 
determined.  The present study was designed to test the effects of a genetic 
reduction in AM in a murine model of LPS-induced septic shock.  
We found that the administration of LPS induced a more severe inflammatory 
response in AM+/- mice than in WT LPS-treated mice.  Regulation of the 
inflammatory response by AM occured at both transcriptional and translational 
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levels.  The expression of two pro-inflammatory cytokines, TNF-α and IL-1β, was 
significantly higher in AM+/- septic mice than in WT septic mice.  In addition, serum 
TNF-α levels were more than 2-fold higher in AM+/- septic mice than in WT septic 
mice.  This data is consistent with previous reports showing that AM reduces the 
production of TNF-α in macrophages and Kupffer cells (30).   
In addition to increased cytokine production, there was also a significant 
elevation in ALT and AST enzyme activity in AM+/- septic mice, when compared to 
WT septic mice.  These results are in agreement with a report by Shindo et al. 
showing that mice overexpressing AM in their vasculature were resistant to LPS-
induced liver damage (25).   
Notably, we failed to observe any differences in end-organ histology (liver, 
kidney), pulmonary edema formation or overall survival of AM+/- septic mice 
compared to control septic mice at all doses and times examined.  We therefore 
conclude that a modest genetic reduction in AM to 50% of WT levels does not 
significantly impact on the pathological morbidity and mortality of septic shock. 
Nevertheless, it is likely that the robust induction of AM expression and the 
modulation of its receptors plays an important role in mediating the septic response.  
Recent studies by others revealed a dynamic change in the expression of 
genes involved in AM signaling during sepsis.  Nagoshi et al. found that TNF-α 
significantly reduced the expression of Calcrl, Ramp1 and Ramp2 in cultured human 
coronary artery smooth muscle cells in a time and dose-dependent manner (19).  
Furthermore, Ono et al. examined the expression of Calcrl and Ramp1, 2, and 3 in 
several tissues from LPS-induced septic mice.  Calcrl and Ramp2 expression were 
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significantly decreased in lungs of septic mice, whereas Ramp3 message levels 
were increased approximately 40 fold in lungs after 12 hours of LPS challenge (21).  
Using a polymicrobial model of sepsis, Ornan et al also showed that Ramp3 
expression is elevated in lungs during the early hyperdynamic stage of sepsis, but 
not in the later hypodynamic phase (22).  Similar to these studies, we also found that 
LPS induced a significant change in the expression patterns of genes involved in AM 
signaling, characterized by a “switch” from Ramp2 to Ramp3 expression in the lungs 
of septic animals.  Importantly, we further established that genetic reduction of AM 
does not impact on the magnitude of these changes, since the response to LPS was 
similar in AM+/- and WT mice.  Although some studies have suggested that 
modulation of Ramp2 and Ramp3 may act to alter the clearance of AM peptide, our 
data show that the absolute level of AM peptide does not directly impact on their 
expression. 
We conclude that during septic shock the dynamic modulation of AM and its 
receptors primarily functions to dampen the inflammatory response.  Therefore, our 
in vivo studies using mice with genetically reduced levels of AM support the use of 
AM therapy to help counteract the detrimental effects of inflammation during septic 
shock in humans. 
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Figure 5.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.1. AM gene expression levels before and after LPS challenge.  Total lung 
RNA was prepared from WT and AM+/− mice treated with or without LPS for 2 h.  AM 
gene expression was measured by quantitative RT-PCR.  At least seven animals 
were used in each group. 
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Figure 5.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.2. Gene expression levels of TNF-α and IL-1β following LPS challenge.  
Total lung RNA was prepared from WT and AM+/− mice treated with or without LPS 
for 45 min.  Expression of these genes was measured by quantitative RT-PCR.  
Four mice were used in each group. 
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Figure 5.3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.3. Serum TNF-α levels following LPS challenge.  Serum from WT and 
AM+/− mice was collected by tail-vein bleed at the indicated time points following 
treatment with 100 mg/kg LPS.  TNF-α was analyzed by ELISA. n = 8 for WT mice 
and n = 9 for AM+/− mice. 
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Figure 5.4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.4. Serum (A) ALT and (B) AST levels following LPS challenge.  Serum 
from WT and AM+/− mice treated with or without LPS for 24 h was collected.  At least 
six mice were used in each group. 
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Figure 5.5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.5. AM receptor gene expression in WT and AM+/− mice following LPS 
challenge. Total lung RNA was prepared from WT and AM+/− mice treated with or 
without LPS for 12 h.  Expression of Ramp2, Ramp3 and Calcrl were measured by 
quantitative RT-PCR.  Four mice were used in each group. 
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CHAPTER 6 
CONCLUSIONS 
 
  
 
 
 
 
 
 
 
 
 
 
 
This thesis describes the use of animal models to examine the in vivo role of  
adrenomedullin signaling (AM, CLR, RAMP2 and RAMP3) in different physiological 
contexts including embryonic development, cardiovascular disease and sepsis.  
Since multiple animal models were used to study a variety of biological processes, 
numerous independent conclusions can be made which collectively enhance our 
current understanding of AM signaling and its in vivo physiological actions.  Key 
points and potential future directions for each chapter are outlined below. 
 
Chapter 2 
Key Points 
• Genetic deletion of Calcrl leads to mid-gestational embryonic lethality with severe 
generalized edema and cardiovascular defects.  
• These defects almost identically phenocopy those previously observed in AM 
knockout mice (5), providing the first in vivo genetic evidence that CLR is the primary 
AM receptor. 
Future Directions 
Although Calcrl embryos die in utero with multiple defects, this model still 
holds much potential for helping us better understand the role of CLR in embryonic 
development and cellular function.  Although technically challenging, 
echocardiography can be used to assess blood flow, cardiac function and overall 
development of in utero mouse embryos (20).  Perhaps this state-of-the art 
technology could allow us to observe embryonic development over the course of a 
few days (i.e. from E10.5-E12.5) and provide insights beyond those gleaned from 
traditional phenotyping methods.  Also, a variety of cell types that completely lack 
Calcrl can be generated from knockout embryos.  Fibroblasts, cardiomyocytes and 
endothelial cells are some of the culturable cell types that could be used from these 
mice to study different biological parameters.  For example, endothelial cell cultures 
could be used to test the role of CLR in regulating permeability and may help resolve 
the never-ending debate of why Calcrl knockouts develop such severe edema.  Of 
course, we must not forget that Calcrl heterozygote mice are also available.  Since 
these mice have no obvious defects, they can be used in a variety of physiological 
studies to examine the role of CLR in heart disease, sepsis and kidney function, just 
to name a few.  Additionally, Calcrl+/- mice can be crossed to other mouse models to 
study the effects of different mutations on a “sensitized” Calcrl genetic background.      
 
Chapter 3 
Key Points 
• Because global Calcrl knockouts die in utero with multiple developmental defects, it 
was necessary to study the role of CLR in specific cell types.  Thus, we generated 
mice with a “floxed” Calcrl allele, which could be crossed to any cell-specific Cre 
recombinase mouse line. 
• Floxed Calcrl mice were crossed to α-MHCCre mice (1) to disrupt Calcrl expression 
specifically in cardiomyocytes, while retaining normal expression levels in all other 
cell types.   
• Cardiomyocyte-specific Calcrl knockouts are born at the expected Mendelian ratios 
and survive into adulthood with no obvious defects.  Thus, loss of Calcrl in 
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cardiomyocytes is not the cause of edema or embryonic lethality observed in the 
global knockouts (chapter 2). 
• Cardiomyocyte-specific Calcrl knockouts were tested in two different heart disease 
models – transverse aortic constriction and angiotensin II infusion.  In both models, 
development of cardiac hypertrophy and fibrosis was evident, but there were no 
significant differences between control and knockout animals.   
• No significant differences in cardiomyocyte contractility were observed between 
control and knockout cardiomyocytes.   
Future Directions 
The generation and characterization of cardiomyocyte-specific Calcrl 
knockouts answered a burning question in the AM field: does loss of Calcrl 
expression in the myocardium contribute to the generalized edema and/or 
embryonic lethality?  Since it does not, we are now also crossing the floxed Calcrl 
mice to other Cre lines to study the role of CLR in other cell types.  In fact, our lab 
has already crossed the floxed mice to the Tie2Cre line (12) to delete Calcrl 
specifically in endothelial cells.  As recently reported (JCI, article in press) these 
endothelial-specific Calcrl knockouts die at mid-gestation from severe generalized 
edema, strikingly similar to the original global Calcrl knockouts.  Thus, AM signaling 
through CLR in endothelial cells is necessary for normal embryonic development 
and survival.   
It would be interesting to generate a transgenic mouse line that over-
expresses Calcrl in endothelial cells and cross it to global Calcrl heterozygotes to 
ultimately produce mice that lack Calcrl in all cells except endothelial cells.  Such a 
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strategy would allow us to address whether Calcrl expression in endothelial cells is 
sufficient to maintain normal embryonic development.  Other members of the lab are 
currently crossing floxed Calcrl mice to the SM-22Cre line which is specifically 
expressed in smooth muscle cells (11).  Results from these crosses are yet to be 
determined. 
 Another interesting aspect of this study is the fact that loss of Calcrl in the 
myocardium had no effect on the heart’s response to aortic constriction or 
angiotensin II infusion.  This is surprising, since AM+/- mice suffer more severe 
cardiac hypertrophy and fibrosis than wild-type controls in both of these models (16, 
17).  One possibility is that the role of CLR in the vasculature, rather than the 
myocardium, is more important in regulating the heart’s response to stress.  This 
hypothesis can be tested with a couple of different mouse lines.  First, assuming that 
the smooth muscle cell-specific Calcrl knockouts survive into adulthood with no 
inherent defects, they could be challenged with both the aortic constriction and 
angiotensin II infusion disease models.  Secondly, an inducible endothelial cell-
specific Cre line (VE cadherin) could also be used to examine the endothelial-
specific role of CLR in regulating the cardiac response to stress.        
 
Chapter 4 
Key Points 
• Generation of Ramp2 and Ramp3 knockout mice is described.   
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• Ramp2 knockouts die in utero at ~E14.5, while Ramp3 knockouts are born at the 
expected Mendelian ratios and, except for reduced body mass at old age, have no 
obvious phenotypic defects.  
• While several reports have consistently demonstrated that both RAMP2 and 
RAMP3 interact with CLR to confer an AM receptor (2, 3, 8-10, 14, 18), our study 
suggests that RAMP2 is the primary RAMP involved in AM signaling, at least during 
embryonic development.  Further studies are required to determine the in vivo role of 
RAMP3. 
Future Directions 
 Several future directions stem from this study.  Since Ramp2 knockouts are 
embryonic lethal the most obvious direction is to generate a floxed Ramp2 allele that 
could be deleted in a cell-type-specific manner.  Another interesting mouse model 
would be one in which the coding sequence for Ramp2 is replaced with the coding 
sequence for Ramp3.  Thus, in addition to expressing Ramp3 in its normal temporal 
and spatial expression pattern, this model would also express Ramp3 when and 
where Ramp2 are normally expressed.  The main question would be whether or not 
Ramp3 can rescue the embryonic lethality that results from a loss of Ramp2.  This 
experiment would provide insight into how the different RAMPs are utilized in AM 
signaling and may reveal significant functional differences between them. 
 It is surprising that Ramp3 knockout mice are almost completely normal.  
Ramp3 expression is elevated in several conditions, including cardiovascular 
disease and sepsis (18, 19, 28).  As stated in chapter 5, Ramp3 expression is 
elevated almost 30 fold in lungs of mice that were treated with LPS.  Pilot studies 
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from our lab showed that Ramp3-/- mice respond similarly (inflammation and 
survival) to wild-type controls when challenged with LPS.  Future studies directed at 
why Ramp3 is so robustly elevated in response to LPS would be interesting.  Is the 
Ramp3 transcriptional response dependent on NF-κB and/or cytokines?  
Determining which cell-types (i.e. macrophages, neutrophils, endothelial cells) 
Ramp3 is elevated in might provide clues to the function it serves in response to 
LPS or other inflammatory factors.  Is vascular AM responsiveness altered when 
RAMP3 is absent?  These questions and many more would help to fill a major gap in 
our understanding of the role RAMP3 plays in sepsis and inflammation.     
 Ramp3 expression is also significantly elevated in the myocardium in 
response to angiotensin II (15).  To further study the role of RAMP3 in the 
cardiovascular response to angiotensin II we are currently crossing Ramp3-/- animals 
to mice that over-express renin (RenTgMK).  These RenTgMK mice develop severe 
cardiac hypertrophy and fibrosis due to consistently high plasma renin and 
angiotensin II levels (4).  The goal of this study is to determine if Ramp3-/- mice 
respond differently (i.e. cardiac and renal damage) to chronically high angiotensin II 
levels than wild-type controls treated in the same manner.       
 
Chapter 5 
Key Points 
• Mice heterozygous for the AM gene (AM+/-) were used to examine the role of AM in 
regulating the inflammatory response to LPS-induced septic shock. 
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• AM+/- mice experienced a much more severe inflammatory response, characterized 
by inflammatory cytokine levels and markers of liver damage, than wild-type control 
mice.   
• The same Ramp2, Ramp3 and Calcrl expression pattern which occurs following 
LPS challenge in wild-type mice also occurred in AM+/- mice, suggesting that the 
level of AM peptide during septic shock does not influence the transcriptional 
regulation of its receptor components.  
Future Directions 
 Chapter 5 demonstrates the important role of AM in regulating the 
inflammatory response to LPS-induced septic shock.  This study is supported by 
several other reports which describe AM as a potent anti-inflammatory factor as well 
as a key regulator of the hemodynamic response during septic shock (23, 25-27).  
For the most part, AM is beneficial in septic shock and is a likely therapeutic 
candidate for patients suffering from this condition.  However, it is well-known that 
vascular responsiveness to AM is reduced during the later stages of sepsis, when 
multiple organ failure begins to occur (24).  This change in AM responsiveness is 
probably due to the drastic reduction of Ramp2 and Calcrl expression following 
prolonged exposure to LPS or infection.  Therefore, in order for AM to be used as an 
effective therapeutic, we must find a way to maintain vascular responsiveness to AM 
throughout the course of sepsis.   
 Pentoxifylline (PTX) is an anti-inflammatory agent that has been shown to 
have several beneficial effects in sepsis, including maintenance of vascular AM 
responsiveness (13, 22).  Whether or not PTX does this by solely acting to reduce 
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inflammatory cytokines is unclear.  It is possible that PTX also alters AM signaling 
properties independently of its anti-inflammatory effects.   A future study aimed at 
examining the effects of PTX on AM signaling components may help to enhance our 
understanding of the role AM plays in sepsis and how AM could be used clinically to 
treat patients. 
 Other future experiments could be designed to investigate the transcriptional 
regulation of AM following LPS exposure.  Although it is well-known that AM is 
elevated in response to LPS and cytokines (7), little is known about how it is 
transcriptionally regulated at the promoter level.  NF-κB and STAT3 are two 
transcription factors that are activated in response to LPS and may be involved in 
regulating AM transcription (6, 21). 
 
Summary 
Clearly, AM and its signaling partners are involved in a variety of biological 
activities.  Much of our current understanding of AM signaling had previously come 
from in vitro studies or “non-genetic” animal models.  Using modern methods in gene 
targeting, I have presented some of the first in vivo genetic evidence which supports 
many of those earlier studies.  Additionally, novel concepts were introduced which 
will enhance our understanding of AM biology and direct the course of future studies.    
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